WO2000012466A1

WO2000012466A1 - Formamide compounds as therapeutic agents

Info

Publication number: WO2000012466A1
Application number: PCT/US1999/019304
Authority: WO
Inventors: Robert Carl Andrews; Marc Werner Andersen; Jennifer Badiang Stanford; Dulce Garrido Babacz; Joseph Howing Chan; David John Cowan; Michael David Gaul; Darryl Lynn Mcdougald; David Lee Musso; Michael Howard Rabinowitz; Robert William Wiethe
Original assignee: Glaxo Group Ltd
Current assignee: Glaxo Group Ltd
Priority date: 1998-08-26
Filing date: 1999-08-25
Publication date: 2000-03-09
Anticipated expiration: 2001-02-26
Also published as: AU5688999A

Abstract

A family of compounds having general structural formula (I), where W is a reverse hydroxamic acid group, and R1, R2, R3, R4, R5 and R6 are as described in the specification, or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof. Also described are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine.

Description

FORMAMIDE COMPOUNDS AS THERAPEUTIC AGENTS

FIELD OF THE INVENTION

The present invention provides novel compounds, novel compositions, methods of their use and methods of their manufacture, such compounds generally pharmacologically useful as agents in those disease states alleviated by the inhibition or antagonism of matrix metalloproteases, metalloproteases, and/or tumor necrosis factor-alpha (TNF), which pathologically involve aberrant extracellular matrix degradation, shedding of cell surface protein ectodomains, and/or TNF synthesis, such disease states including arthritis, tumor metastasis and diabetes. The aforementioned pharmacologic activities are useful in the treatment of mammals.

More specifically, the compounds of the present invention can be used in the treatment of rheumatoid arthritis, osteoarthritis, inflammatory bowel syndromes, periodontal disease, aberrant angiogenesis, tumor invasion and metastasis, corneal ulceration and the complications of diabetes. At the present time, there is a need in the areas of rheumatology, oncology, dentistry, opththalmology, gastroenterology, cardiology, neurology, nephrology, infectious disease and endocrinology therapy for such agents.

BACKGROUND OF THE INVENTION

The matrix metalloprotease (MMP) family of zinc endoproteases includes fibroblast collagenase (MMP-1, collagenase-1), neutrophil collagenase (MMP-8, collagenase-2), chondrocyte collagenase (MMP-13, collagenase-3), gelatinases A and B (MMP's 2 and 9), and members of the stromelysin family such as stromelysin-1 (MMP-3), stromelysin-3 (MMP-11), and matrilysin (MMP-7). These enzymes accelerate breakdown of connective tissue by catalyzed resorption of the extracellular matrix. This is a feature of diverse pathologies; therefore, inhibitors of one or more of the matrix metalloproteases would have utility in a wide range of disease states such as in abrogating the initiation of tumor metastasis and angiogenesis and in halting the pathogenesis of demyelinating diseases of the nervous system, multiple sclerosis being one example. MMP inhibitors would also find utility in diseases involving connective tissue degradation in the joint, as occurs in osteoarthritis and rheumatoid arthritis. MMP's-1 and -3 have been found in elevated levels in the synovial fluid of patients with rheumatoid arthritis and osteoarthritis.

Collagenase-3 (MMP-13) is a member of the family of MMP's which preferentially digest collagen. Collagenase-3 is one of the more newly characterized MMP's; biochemical studies on the recombinant protein have demonstrated that it cleaves type II collagen, the predominant matrix component of articular cartilage, more efficiently than either MMP-1 or

MMP-2 and that it is expressed by chondrocytes in osteoarthritic cartilage. These data would implicate collagenase-3 as a significant target in rheumatoid arthritis and osteoarthritis for inhibition by MMP inhibitors.

Compounds which inhibit the activities of one or more of the matrix metalloproteases are recognized as having therapeutic benefit in one or more pathologies where MMP activity is upregulated, such as: i) inflammatory/autoimmune diseases, including but not limited to rheumatoid arthritis, osteoarthritis, Crohn's disease and other inflammatory bowel diseases, periodontal disease, gingivitis, and corneal ulceration; ii) cardiovascular diseases, including but not limited to atherosclerosis and restenosis; iii) metabolic diseases, including but not limited to complications of diabetes, osteoporosis, and other disorders involving resorption of bone; iv) neurologic diseases, including but not limited to multiple sclerosis and other demyelination ailments; v) diseases of cancer and malignancy, including but not limited to cancers of the oral cavity and pharynx (lip, tongue, mouth, pharynx), esophagus, stomach, small intestine, large intestine, rectum, liver and biliary passages, pancreas, larynx, lung, bone, connective tissue, skin, colon, breast, cervix uteri, corpus endometrium, ovary, prostate, testis, bladder, kidney and other urinary tissues, eye, brain and central nervous system, thyroid and other endocrine gland, leukemias (lymphocytic, granulocytic, monocytic), Hodgkin's disease, non-Hodgkin's lymphomas, multiple myeloma, tumor invasion, and metastatic and angiogenic events thereof; vi) renal diseases, including but not limited to nephrotic syndromes and glomerulonephritis; and vii) infectious diseases, including but not limited to those mediated by viruses, bacteria, and fungi; viii) respiratory diseases, including but not limited to emphysema and COPD.

Many inhibitors of matrix metalloproteases have been disclosed, including some structure activity relationships for a series of carboxylalkylamine inhibitors. These molecules are exemplary for MMP inhibitors in general. They generally embody a functional group capable of tightly binding the zinc cofactor at the enzyme active site, which is contained within a peptidic or pseudopeptide structure. Zinc binding groups among the MMP inhibitor art have included hydroxamic acid, reverse hydroxamic acid, thiol, carboxylate, and phosphinate. Hydroxamate metalloprotease inhibitors disclosed in the art usually have the following general structure (I):

(I) where W is a zinc-chelating acyl derivative group of the formula -C(0)NHOH (which by convention and in this application are referred to as "forward hydroxamates") or a zmc- chelatmg substituted amme group of the formula -NH(OH)C(0)R (which by convention and m this application are referred to as "reverse hydroxamates"), where R is usually hydrogen or alkyl. The other substituents vary accordmg to specifications expressed by the art disclosure. It is understood and demonstrated that variations in these substituents can have dramatic effects on potency and selectivities between the matrix metalloproteases.

Suppression of MMP activity in conditions characterized by its overproduction would be of benefit, and compounds which inhibit MMP's would act in this manner at a specific target and be useful and of benefit. The present invention fills this need by providing potent, specific, orally or parenterally active inhibitors of matrix metalloproteases.

Tumor necrosis factor- (TNFα), hereinafter called "TNF", is a mammalian protein capable of inducing cellular effects by virtue of its interaction with specific cellular receptors. It was initially characterized and so named due to its ability to cause death of cancerous cells. It is produced primarily by activated monocytes and macrophages. Human TNF is produced as a larger pro-form of 26 kD which is processed to a secreted 17 kD mature form by proteolytic processing of the alanme-76 - valme-77 peptide bond.

Recently, certain compounds having matrix metalloprotease - inhibiting activity have been found to inhibit the release of mature 17 kD TNF from cells. Further, these inhibitors also protect mice from a lethal dose of endotoxin indicating that the compounds can inhibit TNF secretion in vivo. These compounds inhibit the cell-associated proteolytic processing of the 26 kD pro-TNF to the mature 17 kD form. The proteolytic activity is thought to reside in an intracellular or cell-associated specific enzyme or family of enzymes, which by convention is called a "TNF convertase", distinct from the matrix metalloproteases but related in that both contain a zinc cation at the active site. TNF convertase enzymatic activity can be detected in monocyte membrane fractions, and the enzyme activity can be inhibited by certain matrix metalloprotease - inhibiting compounds.

A metalloprotease is thought to mediate the proteolysis of the cell - surface IgE receptor CD23. Certain of the CD23 - derived peptides possess proinflammatory biological activities mimicking those of cytokines, including TNFα.

Metalloprotease - like activity is also thought to contribute to the shedding of certain cell surface protein ectodomains such as L-selectin, fibronectin, thyrotropin stimulating hormone receptor, transforming growth factor alpha precursor, low density lipoprotein receptor, beta amyloid precursor protein, interleukin-6 receptor alpha subunit, Fas ligand, CD40 ligand, epidermal growth factor receptor, macrophage colony stimulating factor, interleukin- 1 receptor type II, CD30, and tumor necrosis factor receptors type I and II.

TNF is known to mediate many biological responses in vivo. Preclinical and clinical studies in animals and humans with specific TNF neutralizing antibodies, soluble TNF receptor constructs, and TNF detection techniques have implicated TNF as a mediator in numerous pathologies. The compounds of the present invention by virtue of their activity in inhibiting TNF production and/or their activity in preventing cell surface protein ectodomain shedding should show utility in the treatment of diverse pathologies such as; i) inflammatory/autoimmune diseases, including but not limited to rheumatoid arthritis, osteoarthritis, Crohn's disease and other inflammatory bowel diseases and inflammatory gastrointestinal diseases, and systemic lupus erythematosis; ii) reperfusion injuries, such as those caused by an initial ischemic event; iii) systemic inflammatory response syndromes, including but not limited to sepsis, burn injury, pancreatitis, and adult respiratory distress syndrome; iv) allergic and dermatologic diseases, including but not limited to delayed type hypersensitivity, psoriasis, asthma, eczema, allergic rhinitis, and allergic conjunctivitis; v) cardiovascular diseases, including but not limited to hyperlipidemia, myocardial infarction, atherosclerosis, chronic obstructive pulmonary disease, and restenosis; vi) metabolic diseases, including but not limited to osteoporosis, obesity, and diabetes; vii) neurologic diseases, including but not limited to Alzheimer's disease, Parkinson's disease, multiple sclerosis, aneurism, and stroke; viii) transplant rejection, including but not limited to organ transplant rejection and graft versus host disease; ix) diseases of cancer and malignancy, including but not limited to cancers of the oral cavity and pharynx (lip, tongue, mouth, pharynx), esophagus, stomach, small intestine, large intestine, rectum, liver and biliary passages, pancreas, larynx, lung, bone, connective tissue, skin, colon, rectum, breast, cervix uteri, corpus endometrium, ovary, prostate, testis, bladder, kidney and other urinary tissues, eye, brain and central nervous system, thyroid and other endocrine gland, leukemias (lymphocytic, granulocytic, monocytic), Hodgkin's disease, non- Hodgkin's lymphomas, multiple myeloma, tumor invasion, and metastatic and angiogenic events thereof; x) renal diseases, including but not limited to nephrotic syndromes and glomerulonephritis; xi) cachexia and related wasting syndromes; xii) infectious diseases, including but not limited to HIV infection and neuropathy, Epstein- Barr viral infection, herpes viral infection, malaria, meningitis, schistosomiasis, leprosy, hepatitis (which includes hepatitis A, hepatitis B, and hepatitis C), infectious arthritis, leishmamasis, tuberculosis, Lyme disease, and viral encephalitis; xni) effects of disease therapy, including but not limited to cytokine therapy, chemotherapy, radiation therapy and therapies using anti-T-cell antibodies or cytotoxm-antibody conjugates; and xiv) ocular diseases, including but not limited to diabetic retinopathy and macular degeneration.

Suppression of TNF activity m conditions characterized by its overproduction would be of benefit, and compounds which inhibit TNF convertase would act in this manner at a specific target and be useful and of benefit. The present invention fulfills this need by providing potent, specific, orally or parenterally active inhibitors of matrix metalloproteases, including potent, specific, orally or parenterally active inhibitors of TNF-alpha release from monocyte cells acting via inhibition of TNF-alpha converting enzyme (TNFc).

Suppression of shedding of cell surface protein ectodomams m conditions characterized by an overactivity of such a shedding enzyme or enzymes would be of benefit, and compounds which inhibit this cell surface protein ectodomain shedding would be useful and of benefit. The present invention fulfills this need by providing potent, orally or parenterally active inhibitors of shedding of cell surface protein ectodomams acting via inhibition of one or more specific enzymes which mediate this proteolytic event.

Furthermore, as described above, suppression of CD23 proteolysis m conditions characterized by an overabundance of CD23 proteolytic fragments would be of benefit, and compounds which inhibit CD23 proteolysis would be useful and of benefit. The present invention fulfills this need by providing potent orally or parenterally active inhibitor of CD23 proteolysis acting via inhibition of one or more specific enzymes which mediate this proteolytic event.

SUMMARY OF THE INVENTION

Accordingly it is an object of the present invention to provide a potent, specific, orally or parenterally active inhibitor of MMP's.

It is another object of the present invention to provide a potent, specific, orally or parenterally active inhibitor of TNF-alpha release from monocyte cells acting via inhibition of TNF-alpha converting enzyme (TNFc).

A further object of the present invention to provide a potent, orally or parenterally active inhibitor of shedding of cell surface protein ectodomams acting via inhibition of one or more specific enzymes which mediate this proteolytic event.

It is yet another object of the present invention to provide a potent orally or parenterally active inhibitor of CD23 proteolysis acting via inhibition of one or more specific enzymes which mediate this proteolytic event.

It is therefore an object of the present invention to provide a compound of the formula:

₅

(ll) where R, is ■NVvVV

where A] is alkylene, alkenylene, alkynylene, or a direct bond;

A₂ is O, S, SO, S0₂, or a direct bond;

A₃ is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, aryl, or hydrogen;

R₂ is

D '₄. \

D;

— vVV

where D] is

• or a direct bond, D₂ is alkylene, alkenylene, alkynylene, or a direct bond,

D₃ is cycloalkylene, cycloalkenylene, heterocyclylene, arylene, hetereroarylene, or a direct bond,

D₄ is alkyl, aryl, heteroaryl, or hydrogen;

R₃ is hydrogen or lower alkyl; R, is

where Ej_. is alkylene, alkenylene, alkynylene, or a direct bond, E₂ is S, O, SO, S0₂, C(0)0, OC(O), NR₇, C(0)NR₇, NR₇C(0), S0₂NR₇, or a direct bond, where R₇ is as defined below;

E₃ is alkylene, cycloalkylene, cycloalkenylene, arylene, heterocyclylene, heteroarylene, or a direct bond; E is

E₅ is lower alkyl or hydrogen; R₅ is hydrogen or lower alkyl; Re is z₂

where Zi is heteroarylene or a direct bond;

Z₂ is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, aryl, NR₈R₉, OR₈, or hydrogen, where R₈ and R₉ are as defined below; and R₇, R₈, and R₉ are, independently, hydrogen, alkyl, alkynyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or heteroaryl; or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a family of compounds having the general structural formula:

(I)

or a pharmaceutically acceptable salt, solvate, biohydrolyzable esters, biohydrolyzable amides, affinity reagents, or prodrugs thereof, wherein

W is a reverse hydroxamic acid group;

Ri is a substituent other than hydrogen;

R₄ is a lipophilic substituent containing a nitro - substituted guanidine group, and;

Re is hydrogen, or an alkyl or heteroaryl substituent.

Such compounds are novel and are unknown in the art and, given the appropriate choice of Rj, R₂, R₃, R₄, R₅, and R₆ as described herein, show potent inhibition of MMP's, cell-free TNF convertase enzyme and TNF release from cells, and in some cases inhibit TNF convertase and TNF release from cells in preference to matrix metalloproteases. The selection of R_<; as heteroaryl in combination with an appropriate choice of R_{I }} R₂, R₃, R₄, and R₅ as described hereinis beneficial in achieving increased potency against TNF release from cells relative to inhibition of MMP's. Such molecules can be selective for TNF inhibition over MMP's and can possess an improved therapeutic profile where inhibition of one or more of the matrix metalloproteases is associated with an adverse biological response or abnormal pathology. An appropriate choice of Ri, R₂, R₃, R₄, R₅, and R₆ as described herein is also beneficial in achieving selective inhibition of one or more of the matrix metalloproteases (for example, collagenase-3) in preference to TNF convertase inhibition and inhibition of TNF release from whole cells. In particular, reverse hydroxamate compounds of the present invention include those of the formula (II):

(II) where

R, is

K where A, is alkylene, alkenylene, alkynylene, or a direct bond;

A₂ is

O, S, SO, S0₂, or a direct bond;

R₂ is

where

D, is

or a direct bond,

D₂ is alkylene, alkenylene, alkynylene, or a direct bond,

D₄ is alkyl, aryl, heteroaryl, or hydrogen;

R₃ is hydrogen or lower alkyl;

-^ vvV

_/ E,

Λ X

where Ei is alkylene, alkenylene, alkynylene, or a direct bond,

E₂ is S, O, SO, S0₂, C(O)O, OC(O), NR₇, C(0)NR₇, NR₇C(0), S0₂NR₇, or a direct bond, where R₇ is as defined below; E₃ is alkylene, cycloalkylene, cycloalkenylene, arylene, heterocyclylene, heteroarylene, or a direct bond;

E₄ is

E₅ is lower alkyl or hydrogen;

R₅ is hydrogen or lower alkyl;

e is

Z

where

Z] is heteroarylene or a direct bond;

Z₂ is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, aryl, NR₈R₉, OR₈, or hydrogen, where R₈ and R₉ are as defined below; R₇, R₈, and R₉ are, independently, hydrogen, alkyl, alkynyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or heteroaryl;

or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof.

Compounds of the present invention which are currently preferred for their high biological activity are listed below in Table 1 ; variables below are with reference to the generic structure (I).

Table I

(I)

Compounds of the present invention which are currently preferred for their biological activity are listed by name below in Table 2.

Table 2

Preferred embodiments of the invention include compounds of general formula (II) where

R] is methyl, trifluoromethyl, ethyl, phenylsulfanylmethyl, phenylsulfonylmethyl, thιophene-2-sulfanylmethyl, thιophene-2-sulfonylmethyl, isopropyl, 3 -methyl- 1 -butyl, benzyloxymethyl, 2-benzyloxy-l -ethyl, benzyl, n-propyl, 3,3,3-tπfluoro-l-propyl, or cyclopropyl;

R₂ is isobutyl, cyclohexylmethyl, 3 -(2-furyl)-l -propyl, 3 -(4-bιphenyl)-l -propyl, 4- methylcyclohexylmethyl, cycloheptylmethyl, cyclohexyl, 5-methylthιophene-2-methyl, 4- phenyl-1 -butyl, 3-phenyl-l-propyl, or benzyl;

R₃ is hydrogen, methyl, or ethyl; } is 3-(nιtroιmmo-amιno)methylammo-l -propyl, 3-(nιtroιmιno-amιno)methyl- ethylammo- 1 -propyl, 3-(nιtroιmmo-ammo)methyl-methylamιno- 1 -propyl, 3 -(mtroimmo- ammo)methyl-ιsopropylammo- 1 -propyl, 2-(nιtroιmmo-amιno)methylamιno- 1 - ethylaminocarbonyl ethyl, 2-(nitroimino-amino)methylamino- 1 -ethylaminocarbonylmethyl, 4- (nitroimino-amino)methylamino- 1 -butyl, or 4-(nitroimino-amino)methylamino-2-butyl;

R₅ is hydrogen, methyl, ethyl, or n-propyl; and

Re is hydrogen, methyl, 5-ethyl-2-thiazolyl, cyclopropyl, cyclobutyl, cycloheptyl, 2,2,2-trifluoroethyl, cyclopentyl, 3-cyclopenten-l-yl, 2-pyridyl, l,3,4-thiadiazol-2-yl, or 2- thiazolyl.

Particularly preferred embodiments of the invention include compounds of general formula (II) where R] is methyl, isopropyl, benzyl, n-propyl, 3,3,3-trifluoro-l-propyl, or cyclopropyl;

R₂ is isobutyl, cyclohexylmethyl, 4-methylcyclohexylmethyl , 5 -methyl thiophene-2- methyl, 3-phenyl-l -propyl, or benzyl;

R₃ is hydrogen;

R₄ is 3 -(nitroimino-amino)methylamino-l -propyl, or 4-(nitroimino- amino)methylamino-2-butyl;

R₅ is hydrogen; and

R₆ is hydrogen, methyl, or 2-thiazolyl.

More particularly preferred embodiments of the invention include compounds of general formula (II) where

Ri is methyl, n-propyl, or 3,3,3-trifluoro-l-propyl;

R₂ is isobutyl, 3-phenyl-l -propyl, or benzyl;

R₃ is hydrogen;

R is 3-(nitroimino-amino)methylamino-l -propyl; R₅ is hydrogen; and

R₆ is hydrogen, methyl, or 2-thiazolyl. The compounds of the present invention are inhibitors of matrix metalloproteases,

TNF converting enzyme, and TNF activity from whole cells. The compounds of the present invention may also inhibit shedding of pathologically significant cell surface protein ectodomains. The compounds of the present invention may also inhibit proteolysis of CD23. The invention described herein is additionally directed to pharmaceutical compositions and methods of inhibiting matrix metalloprotease and/or TNF activity and/or CD23 proteolytic fragment activity in a mammal, which methods comprise administering to a mammal in need of a therapeutically defined amount of a compound of formula (I) or (II), defined above, as a single or polymorphic crystalline form or forms, an amorphous form, a single enantiomer, a racemic mixture, a single stereoisomer, a mixture of stereoisomers, a single diastereoisomer, a mixture of diastereomers, a solvate, a pharmaceutically acceptable salt, a solvate, a prodrug, a biohydrolyzable ester, or a biohydrolyzable amide thereof.

According to a further aspect of the present invention there is provided a compound of formula (II) as defined above or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof for use in therapy.

Thus, the present invention provides a method of inhibiting a matrix metalloprotease, comprising the step of administering to a mammal in need thereof a pharmacologically effective amount of a compound of the present invention. The invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of a compound of the present invention sufficient to inhibit a matrix metalloprotease. A matrix metalloprotease- inhibiting amount can be an amount that reduces or inhibits a matrix metalloprotease activity in the subject.

According to a further aspect of the present invention there is also provided the use of a compound of formula (II) as defined above or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof in the preparation of a medicament for inhibiting a matrix metalloprotease.

The present invention further provides a method of inhibiting the intracellular release of tumor necrosis factor alpha, comprising the step of administering to a mammal in need thereof a pharmacologically effective amount of a compound of the present invention. The invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of a compound of the present invention sufficient to inhibit cellular release of mature tumor necrosis factor. An amount sufficient to inhibit cellular release of mature tumor necrosis factor can be an amount that reduces or inhibits cellular release of mature tumor necrosis factor in the subject.

According to a further aspect of the present invention there is also provided the use of a compound of formula (II) as defined above or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof in the preparation of a medicament for inhibiting the intracellular release of tumor necrosis factor alpha.

Also provided is a method of inhibition of shedding of cell surface protein ectodomains, comprising the step of administering to a mammal in need thereof a pharmacologically effective amount of a compound of the present invention. The invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of a compound of the present invention sufficient to inhibit shedding of cell surface protein ectodomains. An amount sufficient to inhibit shedding of cell surface protein ectodomains can be an amount that reduces or inhibits shedding of one or more cell surface protein ectodomains, such as L-selectin, fibronectin, thyrotropin stimulating hormone receptor, transforming growth factor alpha precursor, low density lipoprotein receptor, beta amyloid precursor protein, interleukin-6 receptor alpha subunit, Fas ligand, CD40 ligand, epidermal growth factor receptor, macrophage colony stimulating factor, interleukin-1 receptor type II, CD30, and tumor necrosis factor receptors type I and II, in the subject.

According to a further aspect of the present invention there is also provided the use of a compound of formula (II) as defined above or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof in the preparation of a medicament for inhibiting the shedding of cell surface protein ectodomains.

Also provided is a method of inhibiting CD23 proteolysis, comprising the step of administering to a mammal in need thereof a pharmacologically effective amount of a compound of the present invention. The invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of a compound of the present invention sufficient to inhibit CD23 proteolysis. An amount sufficient to inhibit CD23 proteolysis can be an amount that reduces or inhibits CD23 proteolysis in the subject.

According to a further aspect of the present invention there is also provided the use of a compound of formula (II) as defined above or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof in the preparation of a medicament for inhibiting CD23 proteolysis. Additionally provided is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of a compound of the present invention sufficient to decrease, or inhibit, a malignant growth.

According to a further aspect of the present invention there is also provided the use of a compound of formula (II) as defined above or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof in the preparation of a medicament for inhibiting the growth of tumor metastases.

Further, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of a compound of the present invention sufficient to treat arthritis. Such an amount can be an amount that relieves, i.e., reduces or eliminates, one or more physiologic characteristic of arthritis.

Accordmg to a further aspect of the present invention there is also provided the use of a compound of formula (II) as defined above or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof in the preparation of a medicament for treating arthritis.

Also provided is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of a compound of the present invention sufficient to treat diabetes. Such an amount can be an amount that reduces or eliminates one or more of the complications associated with diabetes.

According to a further aspect of the present invention there is also provided the use of a compound of formula (II) as defined above or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof in the preparation of a medicament for treating diabetes.

Also provided is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of a compound of the present invention sufficient to treat periodontal disease. Such an amount can be an amount that reduces or eliminates one or more of the complications associated with periodontal disease. According to a further aspect of the present invention there is also provided the use of a compound of formula (II) as defined above or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof in the preparation of a medicament for treating periodontal disease.

Additionally, the present invention contemplates treating any of these diseases/conditions in a subject by administering to the subject the recited pharmaceutical composition.

The compounds of the present invention can be administered to any mammal in need of inhibition of matrix metalloprotease activity, CD23 proteolysis, shedding of cell surface protein ectodomains and/or TNF activity. Such mammals can include, for example, horses, cows, sheep, pigs, mice, dogs, cats, primates such as chimpanzees, gorillas, rhesus monkeys, and, most preferably humans.

Certain examples of the invention also are orally or parenterally bioavailable in animals and possess oral or parenteral activity in animal models of disease.

Salts encompassed within the term "pharmaceutically acceptable salts" refer to non- toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid or by reacting the acid with a suitable organic or inorganic base. Representative salts include the following salts: Acetate, Benzenesulfonate, Benzoate, Bicarbonate, Bisulfate, Bitartrate, Borate, Bromide, Calcium Edetate, Camsylate, Carbonate, Chloride, Clavulanate, Citrate, Dihydrochloride, Edetate, Edisylate, Estolate, Esylate, Fumarate, Gluceptate, Gluconate, Glutamate, Glycollylarsamlate, Hexylresorcinate, Hydrabamine, Hydrobromide, Hydrocloride, Hydroxynaphthoate, Iodide, Isethionate, Lactate, Lactobionate, Laurate, Malate, Maleate, Mandelate, Mesylate, Methylbromide, Methylnitrate, Methylsulfate, Monopotassium Maleate, Mucate, Napsylate, Nitrate, N-methylglucamine, Oxalate, Pamoate (Embonate), Palmitate, Pantothenate, Phosphate/diphosphate, Polygalacturonate, Potassium, Salicylate, Sodium, Stearate, Subacetate, Succinate, Tannate, Tartrate, Teoclate, Tosylate, Triethiodide, Trimethylammonium and Valerate.

Other salts which are not pharmaceutically acceptable may be useful in the preparation of compounds of formula (I) or (II) and these form a further aspect of the invention.

Also included within the scope of the invention are the individual enantiomers of the compounds represented by formula (I) or (II) above as well as any wholly or partially racemic mixtures thereof. The present invention also covers the individual enantiomers of the compounds represented by formula above as mixtures with diastereoisomers thereof in which one or more of the three stereocenters are inverted.

As used herein, the term "lower" refers to a group having between one and six carbons.

As used herein, the term "alkyl" refers to a straight or branched chain hydrocarbon having from one to ten carbon atoms, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Examples of "alkyl" as used herein include , but are not limited to, n-butyl, n-pentyl, isobutyl, and isopropyl, and the like.

As used herein, the term "alkylene" refers to a straight or branched chain divalent hydrocarbon radical having from one to ten carbon atoms, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Examples of "alkylene" as used herein include, but are not limited to, methylene, ethyl ene, and the like.

As used herein, the term "alkenyl" refers to a hydrocarbon radical having from two to ten carbons and at least one carbon - carbon double bond, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed.

As used herein, the term "alkenylene" refers to an straight or branched chain divalent hydrocarbon radical having from two to ten carbon atoms and one or more carbon - carbon double bonds, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Examples of "alkenylene" as used herein include, but are not limited to, ethene- 1 ,2-diyl, propene-l,3-diyl, methylene- 1,1-diyl, and the like.

As used herein, the term "alkynyl" refers to a hydrocarbon radical having from two to ten carbons and at least one carbon - carbon triple bond, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed.

As used herein, the term "alkynylene" refers to a straight or branched chain divalent hydrocarbon radical having from two to ten carbon atoms and one or more carbon - carbon triple bonds, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Examples of "alkynylene" as used herein include, but are not limited to, ethyne-l,2-diyl, propyne-l,3-diyl, and the like.

As used herein, "cycloalkyl" refers to a alicyclic hydrocarbon group with one or more degrees of unsaturation, having from three to twelve carton atoms, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. "Cycloalkyl" includes by way of example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, and the like.

As used herein, the term "cycloalkylene" refers to an non-aromatic alicyclic divalent hydrocarbon radical having from three to twelve carbon atoms, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Examples of "cycloalkylene" as used herein include, but are not limited to, cyclopropyl- 1,1-diyl, cyclopropyl- 1 ,2-diyl, cyclobutyl- 1,2- diyl, cyclopentyl- 1,3-diyl, cyclohexyl- 1,4-diyl, cycloheptyl- 1,4-diyl, or cyclooctyl- 1,5-diyl, and the like.

As used herein, the term "cycloalkenyl" refers to a substituted alicyclic hydrocarbon radical having from three to twelve carbon atoms and at least one carbon-carbon double bond in the ring system, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Examples of "cycloalkenylene" as used herein include, but are not limited to, 1 - cyclopentene-3-yl, l-cyclohexene-3-yl, l-cycloheptene-4-yl, and the like. As used herein, the term "cycloalkenylene" refers to a substituted alicyclic divalent hydrocarbon radical having from three to twelve carbon atoms and at least one carbon-carbon double bond in the ring system, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Examples of "cycloalkenylene" as used herein include, but are not limited to, 4,5-cyclopentene-l,3-diyl, 3,4-cyclohexene-l,l-diyl, and the like.

As used herein, the term "heterocyclic" or the term "heterocyclyl" refers to a three to twelve-membered heterocyclic ring having one or more degrees of unsaturation containing one or more heteroatomic substitutions selected from S, SO, S0₂, O, or N, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Such a ring may be optionally fused to one or more of another "heterocyclic" ring(s) or cycloalkyl ring(s). Examples of "heterocyclic" include, but are not limited to, tetrahydrofuran, pyran, 1 ,4-dioxane, 1 ,3- dioxane, piperidine, pyrrolidine, morpholine, tetrahydrothiopyran, tetrahydrothiophene, and the like.

As used herein, the term "heterocyclylene" refers to a three to twelve- membered heterocyclic ring diradical having one or more degrees of unsaturation containing one or more heteroatoms selected from S, SO, S0₂, O, or N, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Such a ring may be optionally fused to one or more of another "heterocyclic" rings or cycloalkyl rings. Examples of "heterocyclylene" include, but are not limited to, tetrahydrofuran-2,5-dιyl, morpholme-2,3-dιyl, pyran-2,4-dιyl, l,4-dιoxane-2,3-dιyl, l,3-dιoxane-2,4-dιyl, pιpeπdme-2,4-dιyl, pipeπdine- 1,4-diyl, pyrrolιdme-l,3-dιyl, morpholme-2,4-dιyl, and the like.

As used herein, the term "aryl" refers to a benzene ring or to an optionally substituted benzene ring system fused to one or more optionally substituted benzene rings, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, tefrazolyl, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, alkoxy carbonyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed Examples of aryl include, but are not limited to, phenyl, 2-naphthyl, 1 -naphthyl, and the like.

As used herein, the term "arylene" refers to a benzene ring diradical or to a benzene ring system diradical fused to one or more optionally substituted benzene rings, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, tefrazolyl, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed Examples of "arylene" include, but are not limited to, benzene- 1,4-diyl, naphthalene- 1,8-dιyl, anthracene- 1,4-diyl, and the like.

As used herein, the term "heteroaryl" refers to a five - to seven - membered aromatic ring, or to a polycyclic heterocyclic aromatic ring, containing one or more nitrogen, oxygen, or sulfur heteroatoms, where N-oxides and sulfur monoxides and sulfur dioxides are permissible heteroaromatic substitutions, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, ammo optionally substituted by alkyl, carboxy, tefrazolyl, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed For polycyclic aromatic ring systems, one or more of the rings may contain one or more heteroatoms Examples of "heteroaryl" used herein are furan, thiophene, pyrrole, lmidazole, pyrazole, tπazole, tetrazole, thiazole, oxazole, isoxazole, oxadiazole, thiadiazole, isothiazole, pyridine, pyπdazine, pyrazme, pyπmidme, quinohne, lsoqumolme, benzofuran, benzothiophene, mdole, and mdazole, and the like.

As used herein, the term "heteroarylene" refers to a five - to seven - membered aromatic ring diradical, or to a polycyclic heterocyclic aromatic ring diradical, containing one or more nitrogen, oxygen, or sulfur heteroatoms, where N-oxides and sulfur monoxides and sulfur dioxides are permissible heteroaromatic substitutions, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, am o optionally substituted by alkyl, carboxy, tefrazolyl, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. For polycyclic aromatic ring system diradicals, one or more of the rings may contain one or more heteroatoms. Examples of "heteroarylene" used herein are furan-2,5-diyl, thiophene-2,4-diyl, l,3,4-oxadiazole-2,5-diyl, l,3,4-thiadiazole-2,5- diyl, l,3-thiazole-2,4-diyl, l,3-thiazole-2,5-diyl, pyridine-2,4-diyl, pyridine-2,3-diyl, pyridine-2,5-diyl, pyrimidine-2,4-diyl, quinoline-2,3-diyl, and the like.

As used herein, the term "direct bond", where part of a structural variable specification, refers to the direct joining of the substituents flanking (preceding and succeeding) the variable taken as a "direct bond". Where two or more consecutive variables are specified each as a "direct bond", those substituents flanking (preceding and succeeding) those two or more consecutive specified "direct bonds" are directly joined.

As used herein, the term "alkoxy" refers to the group R_aO-, where R_a is alkyl.

As used herein, the term "alkenyloxy" refers to the group R_aO-, where R_a is alkenyl.

As used herein, the term "alkynyloxy" refers to the group R_aO-, where R_a is alkynyl.

As used herein, the term "alkylsulfanyl" refers to the group R_aS-, where R_a is alkyl.

As used herein, the term "alkenylsulfanyl" refers to the group R_aS-, where R_a is alkenyl. As used herein, the term "alkynylsulfanyl" refers to the group R_aS-, where R_a is alkynyl.

As used herein, the term "alkylsulfenyl" refers to the group R_aS(0)-, where

R_a is alkyl.

As used herein, the term "alkenylsulfenyl" refers to the group R_aS(0)-, where R_a is alkenyl.

As used herein, the term "alkynylsulfenyl" refers to the group R_aS(0)-, where R_a is alkynyl.

As used herein, the term "alkylsulfonyl" refers to the group R_aS0₂-, where R_a is alkyl.

As used herein, the term "alkenylsulfonyl" refers to the group R_aS0₂-, where R_a is alkenyl.

As used herein, the term "alkynylsulfonyl" refers to the group R_aS0₂-, where

R_a is alkynyl.

As used herein, the term "acyl" refers to the group R_aC(0)- , where R_a is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, or heterocyclyl.

As used herein, the term "aroyl" refers to the group R_aC(0)- , where R_a is aryl. As used herein, the term "heteroaroyl" refers to the group R_aC(0)- , where R_a is heteroaryl.

As used herein, the term "alkoxycarbonyl" refers to the group R_aOC(0)-, where R_a is alkyl.

As used herein, the term "acyloxy" refers to the group R_aC(0)0- , where R_a is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, or heterocyclyl.

As used herein, the term "aroyloxy" refers to the group R_aC(0)0- , where R_a is aryl.

As used herein, the term "heteroaroyloxy" refers to the group R_aC(0)0- , where R_a is heteroaryl.

As used herein, the term "optionally" means that the subsequently described event(s) may or may not occur, and includes both event(s) which occur and events that do not occur.

As used herein, the term "substituted" refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated.

As used herein, the terms "contain" or "containing" can refer to in-line substitutions at any position along the above-defined alkyl, alkenyl, alkynyl or cycloalkyl substituents with one or more of any of O, S, SO, S0₂, N, or N-alkyl, including, for example, -CH₂-0-CH₂-, -CH₂-S0₂-CH₂-, -CH₂-NH-CH₃ and so forth. As used herein, the term "solvate" is a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or (II)) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Solvents may be, by way of example, water, ethanol, or acetic acid.

As used herein, the term "biohydrolyzable ester" is an ester of a drug substance (in this invention, a compound of general formula (I) or (II)) which either a) does not interfere with the biological activity of the parent substance but confers on that substance advantageous properties in vivo such as duration of action, onset of action, and the like, or b) is biologically inactive but is readily converted in vivo by the subject to the biologically active principle. The advantage is that, for example, the biohydrolyzable ester is orally absorbed from the gut and is transformed to (I) or (II) in plasma. Many examples of such are known in the art and include by way of example lower alkyl esters, lower acyloxy-alkyl esters, lower alkoxyacyloxyaljcyl esters, alkoxyacyloxy esters, alkyl acylamino alkyl esters, and choline esters. An example of such a biohydrolyzable ester applied to the general formula (II) is illustrated below in general formula (III).

(HI)

As used herein, the term "biohydrolyzable amide" is an amide of a drug substance (in this invention, a compound of general formula (I) or (II)) which either a) does not interfere with the biological activity of the parent substance but confers on that substance advantageous properties in vivo such as duration of action, onset of action, and the like, or b) is biologically inactive but is readily converted in vivo by the subject to the biologically active principle. The advantage is that, for example, the biohydrolyzable amide is orally absorbed from the gut and is transformed to (I) or (II) in plasma Many examples of such are known m the art and include by way of example lower alkyl amides, α-amino acid amides, alkoxyacyl amides, and alkylaminoalkylcarbonyl amides

As used herein, the term "prodrug" includes biohydrolyzable amides and biohydrolyzable esters and also encompasses a) compounds in which the biohydrolyzable functionality in such a prodrug is encompassed in the compound of formula (I) or (II): for example, the lactam formed by a carboxyhc group in R₂ and an amme m R₄, and b) compounds which may be oxidized or reduced biologically at a given functional group to yield drug substances of formula (I) or (II) Examples of these functional groups are, but are not limited to, 1 ,4-dιhydropyπdιne, N-alkylcarbonyl- 1 ,4-dιhydropyrιdme, 1,4- cyclohexadiene, tert-butyl, and the like

As used herein, the term "affinity reagent" is a group attached to the compound of formula (I) or (II) which does not affect its in vitro biological activity, allowing the compound to bind to a target, yet such a group binds strongly to a third component allowing a) characterization of the target as to localization within a cell or other organism component, perhaps by visualization by fluorescence or radiography, or b) facile separation of the target from an unknown mixture of targets, whether proteinaceous or not protemaceous. An example of an affinity reagent according to b) would be biotm either directly attached to (I) or (II) or linked with a spacer of one to 50 atoms selected from the group consisting of C, H, O, N, S, or P in any combination An example of an affinity reagent according to a) above would be fluorescem, either directly attached to (I) or (II) or linked with a spacer of one to 50 atoms selected from the group consisting of C, H, O, N, S, or P m any combination The term "pharmacologically effective amount" shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher or clinician. This amount can be a therapeutically effective amount.

Whenever the terms "alkyl" or "aryl" or either of their prefix roots appear in a name of a substituent (e.g. arylalkoxyaryloxy) they shall be interpreted as including those limitations given above for "alkyl" and "aryl". Alkyl or cycloalkyl substituents shall be recognized as being functionally equivalent to those having one or more degrees of unsaturation. Designated numbers of carbon atoms (e.g. Ci-io) shall refer independently to the number of carbon atoms in an alkyl, alkenyl or alkynyl or cyclic alkyl moiety or to the alkyl portion of a larger substituent in which the term "alkyl" appears as its prefix root.

As used herein, the term "oxo" shall refer to the substituent =0.

As used herein, the term "halogen" or "halo" shall include iodine, bromine, chlorine and fluorine.

As used herein, the term "mercapto" shall refer to the substituent -SH.

As used herein, the term "carboxy" shall refer to the substituent -COOH.

As used herein, the term "cyano" shall refer to the substituent -CN.

As used herein, the term "aminosulfonyl" shall refer to the substituent -S0₂NH₂.

As used herein, the term "carbamoyl" shall refer to the substituent -C(0)NH₂. As used herein, the term "sulfanyl" shall refer to the substituent -S-.

As used herein, the term "sulfenyl" shall refer to the substituent -S(O)-.

As used herein, the term "sulfonyl" shall refer to the substituent -S(0)₂-.

The compounds of formulae (I) and (II) can be prepared readily according to the following reaction Schemes (in which all variables are as defined before) and Examples or modifications thereof using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art, but are not mentioned in greater detail.

The most preferred compounds of the invention are any or all of those specifically set forth in these examples. These compounds are not, however, to be coristrued as forming the only genus that is considered as the invention, and any combination of the compounds or their moieties may itself form a genus. The following examples further illustrate details for the preparation of the compounds of the present invention Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. All temperatures are degrees Celsius unless noted otherwise.

Abbreviations used in the Examples are as follows: g = grams mg = milligrams

L = liters mL = millihters psi = pounds per square inch

M = molar

N = normal mM = millimolar i.v. = intravenous p.o. = per oral s.c. = subcutaneous

Hz = hertz mol = moles mmol = millimoles mbar = millibar rt = room temperature min = minutes h = hours d = days mp = melting point

TLC = thin layer chromatography

Rf = relative TLC mobility

MS = mass spectrometry

NMR = nuclear magnetic resonance spectroscopy

APCI = atmospheric pressure chemical ionization

ESI = electrospray ionization m/z = mass to charge ratio tr = retention time ether = diethyl ether

MeOH = methanol

EtOAc = ethyl acetate TEA = tπethylamme

DIEA = dnsopropylethylamine

BOP = ( 1 -benzotπazolyloxy)tπs(dιmethylamιno)phosphonιum hexafluorophosphate THF = tetrahydrofuran

DMF = N, N-dimefhylformamide

DMSO = dimefhylsulfoxide

LAH = lithium aluminum hydride

TFA = tπfluoroacetic acid EDC =l-ethyl-3-(3-dιmethylamιnopropyl)-carbodπmιde hydrochloride

HOBt = 1 -hydroxybenzotπazole

LDA = lithium dnsopropylamide

THP = tetrahydropyranyl

NMM = N-mefhylmorphohne, 4-methylmoφhohne HMPA = hexamethylphosphoπc tπamide

DMPU = 1,3-dιmethypropylene urea

DMAP =4-dιmethylamιnopyπdme

DBU =l,8-dιazabιcyclo[5.4 0]undec-7-ene ppm = parts per million kD = kiloDalton

LPS = lipopolysacchaπde

PMA = phorbol myπstate acetate

SPA = scintillation proximity assay

EDTA = ethylenediamine tetraacetic acid FBS = fetal bovine serum

PBS = phosphate buffered saline solution

ELISA = enzyme - linked immunosorbent assay Several of the following examples represent pairs of stereoisomers which were separated as diastereoisomers but were not identified therein. Determination and/or preparation of the R and S isomers can advantageously be approached by stereoselective chemical methods, see "Advanced Organic Chemistry", Carey and Sundberg, 3rd edition, Plenum Press, 1990, 596, by analytical methods such as X-ray crystallography, or by determination of biological activity and subsequent correlation to biologically active compounds of known stereochemistry.

GENERAL REACTION SCHEMES

Compounds of the invention may be prepared by methods known in the art, where such a method is shown in reaction Scheme 1.

Reaction Scherre 1

IV V

VII I" R_1; R₂, R₃, R₄, R₅, and R₆ are defined as for formula (II).

RPGi is a protecting group suitable for the hydroxylamine oxygen, such as benzyl or 2- tetr ahy dropyrany 1.

Rio is chosen from the group consisting of hydroxyl, 0-C₆F₅, or halogen. When Rio is hydroxyl, the conversion of (V) to (VII) involves methods known in peptide chemistry; for example, the reaction may be conducted using HOBt in combination with a dehydrating agent such as dicyclohexylcarbodiimide in a suitable solvent, such as DMF. When Rio is 0-C₆F₅, the conversion of (IV) to (V) is conducted by treating (IV) in a suitable solvent such as dichloromethane with pentafluorophenyl trifluoroacetate in the presence of pyridine, or with EDC and pentafluorophenol in a suitable solvent such as dichloromethane. The displacement reaction to produce (VII) is carried out in the presence of a suitable solvent such as dioxane, THF, dichloromethane, or DMF, at a temperature of 0 °C to 140 °C. The reaction is effected in the presence of an organic base such as NMM or TEA. Further, the conversion of (IV) to (VII) may be carried out by reacting (IV) with a dialkyl cyanophosphonate in the presence of NMM or TEA in a solvent such as DMF, followed by addition of (VI). The removal of the RPGi group where RPGi is benzyl may be achieved by hydrogenation of (VII) with palladium on barium sulfate in a suitable solvent such as ethanol or THF, or, where RPGi is 2-tetrahydropyranyl, by hydrolysis with aqueous acetic acid at a temperature of 20 °C to 100 °C.

Reaction Scheme 2 depicts the synthesis of a compound of formula (IV).

Reaction Scheme 2

X XI

XII IV

Ri and R₂ are as defined for formula (II).

RnO is a nucleofugal group such as methanesulfonate or p-toluenesulfonate.

RPGi is as defined for reaction Scheme 1.

The acid of formula (VIII) may be converted to the alcohol of formula (IX) by treatment with HOBt, O-benzylhydroxylamine hydrochloride or 0-(2- tetrahydropyranyl)hydroxylamine, NMM, and a carbodiimide reagent such as EDC in a suitable solvent such as DMF. The alcohol of formula (IX) may be converted to (X) by treatment with methanesulfonyl chloride or p-toluenesulfonyl chloride and pyridine in a suitable solvent such as dichloromethane. The conversion of (X) to (XI) may be conducted by treatment with potassium carbonate in a suitable solvent such as acetone or 2-butanone, at temperature of 20 °C to 90 °C. Alternatively, (IX) may be converted directly to (XI) by treatment with triphenylphosphine and diethyl azodicarboxylate or another azodicarbonyl diester or diamide in a suitable solvent such as THF at a temperature of -78 °C to 50 °C. The compound of formula (XI) may be converted to (XII) by treatment with an inorganic base such as sodium hydroxide in water or water m combination with a water - soluble organic cosolvent such as MeOH or THF, followed by acidification with an acidic solution such as aqueous citric acid or aqueous sodium bisulfate. The compound of formula (XII) may be converted to (IV) by treatment with acetic anhydride and formic acid or by treatment with formic acetic anhydride in pyridme in the presence or absence of a suitable cosolvent such as dichloromethane.

An alternate preparation of compounds of general formulae (XI) and (IV) is depicted in reaction Scheme 3.

Reaction Scherre 3

Ri and R₂ are as defined as for formula (II).

R]₂, R_]3, R₎₄, and Rι₅ may be, independently, alkyl, alkenyl, alkynyl, or hydrogen.

Ri₆ is selected from the group consisting of aryl, heteroaryl, alkynyl, or alkenyl, with the proviso that the unsaturated carbons of alkenyl and alkynyl groups are directly bonded to Li .

Li is selected from the group consisting of bromide, iodide, or frifluoromethanesulfonate. L₂ is trι(lower alkyl)stannyl or -B(OH)₂. RPGi is defined as for reaction scheme 1.

The lactam of general formula (XIII) may be treated with a palladium catalyst such as tetrakιs(tπphenylphosphme)palladιum and R]₆-Lι in a solvent such as acetonitrile m the presence of a tertiary amme base such as NMM at a temperature of from 20 °C to 200 °C to afford (XIV). Reduction of the olefimc group in (XIV) with hydrogen and a metal catalyst such as palladium on carbon and conversion of the lactam (XI) to the acid (IV) proceeds as outlined m reaction Scheme 2 Alternately, the olefin in compounds of general formula (XIV) may be left in place and manipulation of the lactam (XIV) is carried out as descπbed in reaction Scheme 2 to afford (XV) (XV) may be converted to (IV) as described in reaction Scheme 2 with or without reduction of the olefin m (XV), as appropriate. The alkyne (XVI) may be treated with tπ(butyltm) hydride in the presence of a radical initiator such as azobιs(ιsobutyronιtπle) to afford an alkyl tin intermediate (XVII), which may be treated with R₁₆-L₁ and a catalyst such as Pd(PPh₃) a solvent such as DMF in the presence or LiCl to afford (XVIII) Alternately, (XVII) may be treated with iodine in an organic solvent such as ether to afford the destannylated vinyl iodide. The iodide may be treated with R₁₆-L? in the presence of a palladium catalyst such as Pd(PPh₃)₄ in a solvent such as DMF or THF at a temperature of 25 °C to 140 °C to afford (XVIII). The alkyne (XIX) may be treated with R,₆- Li, CuCl or Cul and alkylamine such as TEA in the presence of a catalyst such as Pd(PPh₃) to afford (XX). (XX) and (XVIII) may be manipulated to the intermediate (IV) via the operations described previously.

An alternative route of preparation of compounds of formula (IX) is depicted in reaction Scheme 4. Reaction Scheme 4

II

VIII

IX

Ri and R₂ are as defined as for formula (II). Rπ is lower alkoxy or 1-oxazolidinyl. RPGi is as defined for reaction Scheme 1.

A carbonyl compound of formula (XXI), where Rπ is an alkoxy group such as methoxy or tert-butoxy, may be treated with a strong base such as LDA in a solvent such as THF at a temperature of from -78 °C to 0 °C, followed by treatment with the aldehyde (XXII) to provide (XXIII). Where Rι₇ is a oxazolidinon-1-yl substituent, treatment of (XXI) with a Lewis acid such as di(n-butyl)boron trifluoromethanesulfonate in the presence of DIEA in a suitable solvent such as dichloromethane at a temperature of 0 °C, followed by addition of the aldehyde (XXII) provides (XXIII). Treatment of (XXIII) with aqueous base in the presence or absence of hydrogen peroxide affords (VIII) upon acidification. The acid (VIII) may be converted directly to (IX) as in reaction Scheme 2, or may be treated with a dehydrating agent such a p-toluenesulfonyl chloride in pyridine or with triphenylphosphine and diethyl azodicarboxylate in a suitable solvent such as THF, to afford the lactone (XXIV). Treatment of the lactone (XXIV) with H₂NO-RPGι in the presence of a Lewis acid such as frimethylaluminum in a suitable solvent such as toluene affords the alcohol (IX).

Reaction Scheme 5 depicts the preparation of compounds of general formula (VIII).

Reaction Scheme 5

XXXI XXXIII

XXXIV VIII

Ri and R₂ are as defined for formula (II). R₂₀ is lower alkyl.

RPGi is as defined for reaction Scheme 1. L₃ is bromide, iodide, or tπfluoromethanesulfonyloxy. R]₂, Rι₃ and R_] are as defined for reaction scheme 3.

Rig and R_]9, may be, independently, alkyl, alkenyl, alkynyl, or hydrogen.

The ester of general formula (XXVI), if not commercially available, may be prepared by reaction of ester (XXV) with a strong base such as LDA followed by treatment with the aldehyde (XXII) The resulting hydroxyester (XXVI) may be used directly or converted to the ketoester (XXVII) by oxidation with, for example, pyridimum dichromate in a solvent such as dichloromethane Alternately the acid chloride (XXVIII) may be condensed with 2,2- dιmethyl-4,6-dιoxo-l,3-dιoxane in the presence of pyridme to afford (XXIX), which may be treated with excess R₂₀-OH at a temperature of from 25 °C to 150 °C to provide (XXVII). The ketoester of general formula (XXVII) may be reduced with a reducing agent such as sodium borohydπde to afford the hydroxyester (XXVI). Alternately, a chiral catalyst or chiral ligand in the presence of a reducing agent such as hydrogen or a metal hydride such as borane or LAH may be employed to afford (XXVI) with chiral induction at the newly formed asymmetric center. The alcohol (XXVI) may be converted to (XXX) by treatment with a strong base such as LDA in a suitable solvent such as THF, followed by the addition of R₂-L₃ in the presence or absence of a cosolvent such as DMPU. Where R₂ contains an unsaturated group, (XXX) may be reduced with, for example, hydrogen and a noble metal catalyst, under appropriate conditions. Removal of the ester group by hydrolysis with aqueous hydroxide ion or, m the case where R₂₀ is tert-butyl, by freatment with a strong acid such as TFA, affords (VIII). Hydroxy acid (XXXI) is obtained by hydrolysis of the ester group of (XXVI) with aqueous alkali. (XXXI) may be obtained by treatment of (XXVI) with TFA, where R₂₀ is tert-butyl. Coupling of the hydroxy acid (XXXI) with an allyhc alcohol (XXXII) in the presence of a dehydrating agent such as EDC and a catalyst such as 4-dιmethylammopyπdme provides the ester (XXXIII). Alternately, protection of the alcohol functionality of ester (XXVI) with, for example, a tert-butyldimethylsilyl group, may be required before processing of (XXVI) to the acid. Hydrolysis of the ester grouping of the protected (XXVI) as before followed by activation of the acid functionality as its acid chloride with oxalyl chloride and addition of the alcohol (XXXII) in the presence of an organic base such as TEA provides the ester (XXXIII) with the hydroxyl group protected. Deprotection of the hydroxyl group, if so protected, and treatment of the resulting ester (XXXIII) with a strong base such as LDA in a solvent such as 1 ,2-dimethoxyethane at a temperature of -78 °C, followed by warming of the mixture to a temperature of between 0 °C and 90 °C, followed by acidification of the mixture provides the acid (XXXIV). Reduction of the olefinic group in (XXXIV) with hydrogen and a metal catalyst such as palladium on carbon provides the acid (VIII). Alternately, the olefin in compounds of general formula (XXXIV) may be left in place until a later stage and then saturated with, for example, hydrogen gas in the presence of palladium on carbon.

The preparation of compounds of general formula (VI) is shown in reaction Scheme 6.

Reaction Scheme 6

l

*4 X wXXvV ^{R ■} '4 xxxvi

XXXVIII VI

R₃, R₄, R₅, and Re are as defined for general formula (II). RPG₂ is a protecting group such as tert-butoxycarbonyl or benzyloxycarbonyl. R_2! is hydroxyl or halogen.

The acid of formula (XXXV) may be converted in situ to (XXXVI), where R_2] is bromide, by treatment with bromo-tris(pyrrolidino)phosphonium hexafluorophosphate in a suitable solvent such as DMF in the presence of an organic base such as DIEA. Addition of the amine (XXXVII) in the displacement step in the presence of a suitable solvent such as DMF and an organic base such as DIEA affords the amide (XXXVIII). Alternatively, the intermediate of formula (XXXVI) where R₂₎ is hydroxyl may be treated with carbonyldiimidazole in a solvent such as dichloromethane, followed by treatment with the amine (XXXVII) to afford (XXXVIII). Alternatively, the intermediate of formula (XXXV) may be treated with HOBt, the amine (XXXVII), an organic base such as NMM, and a carbodiimide reagent such as EDC in a suitable solvent such as DMF, at a temperature of 0 °C to 80 °C to provide (XXXVIII). The compound of formula (XXXVIII) may be converted to (VI) by deprotection, conditions being particular to the nature of RPG₂. For example, where RPG₂ is tert-butoxycarbonyl, conversion of (XXVIII) to (VI) may be accomplished by treatment of (XXVIII) with trifluoroacetic acid in the presence or absence of a suitable solvent such as dichloromethane, at a temperature of 0 °C to 50 °C.

A preparation of compounds of general formula (XXXV) is shown in reaction Scheme 7.

Reaction Schema 7

XXXV

R₃, R_4, E], E₂, E₃, and E₅ are as defined for general formula (II). RPG₂ is defined as for reaction scheme 6. R₂₂ is lower alkyl.

The compound (XXXIX) may be treated with an amidinating reagent such as 1- carboxamidino-3,5-dimethylpyrazole in a solvent such as DMF in the presence of tertiary base such as TEA to afford (XL). (XL) may be nitrated by treatment with nitric acid and sulfuric acid at a temperature of from 0 °C to 25 °C. The nitrated product may be converted to (XXXV) by removal of R₂₂; for example, where R₂₂ is lower non tertiary alkyl, freatment with aqueous sodium hydroxide affords (XXXV). Concomitant removal of R₂₂ may occur spontaneously in the nitration step to provide (XXXV). The nifration procedure may afford (XLI) cleanly and (XLI) may be converted to (XXXV) by treatment with RPG₂-C1 and aqueous base (where RPG₂ is benzyloxycarbonyl), or (RPG₂)₂0 and aqueous base, where RPG₂ is tert-butoxycarbonyl. Alternately, the nitration procedure may afford (XLII) cleanly and (XLII) may be converted to (XXXV) by treatment with RPG₂-C1 and aqueous base (where RPG₂ is benzyloxycarbonyl), or (RPG₂)₂0 and aqueous base, where RPG₂ is tert- butoxycarbonyl; removal of the alkyl group R₂ by sapomfication with aqueous base (or, if appropriate and where R₂₂ is tert-butyl, by treatment with tπfluoroacetic acid) provides (XXXV).

Reaction Scheme 8 depicts an alternate preparation of an intermediate of general formula (XXXV).

Reaction Scheme 8

XXXV R₃, R₄ Ei, E₃, and E₅ and R₇ are as defined for general formula (II). R₂₄ is SH, NR₇, or OH.

RPG₂ is defined as for reaction scheme 6. R₂₂ is defined as for reaction scheme 7.

R₂₃ is bromide, iodide, methanesulfonate, or p-toluenesulfonate.

R₂₄ is hydrogen.

(XLIII) and (XLVI) may be treated with a amidinating reagent such as 1- carboxamidino-3,5-dimethylpyrazole in a solvent such as DMF in the presence of tertiary base such as TEA to afford (XLIV) and (XL VII), respectively. Nifration of (XLIV) and (XL VII) with nitric acid and sulfuric acid at a temperature of between 0 °C and 25 °C affords (XLV) and (XL VIII), respectively. The ester (XLIX) may be treated with a) for the case where R₂₄ is OH, NR₇, or SH, (XLV) in the presence of a base such as sodium hydride or potassium carbonate in a suitable solvent such as DMF or THF , or b) for the case where R₂₄ is OH, or NR₇, (XL VIII) in the presence of a dehydrating agent such as EDC in the presence of HOBt and NMM in a solvent such as DMF or CHC1₂, optionally in the presence of DMAP, to provide the intermediate of formula (L). Hydrolysis of the ester group as for reaction scheme 7 provides (XXXV). Reaction scheme 9 depicts an alternate preparation of an intermediate of general formula (XXXIX).

Reaction Scheme 9

XXXIX

R_3ι Ei, E₂, E₃, and E₅ are as defined for general formula (II).

E₆, R₂₃, and R₂₄ are defined as for reaction scheme 8.

RPG₃ is a protecting group such as tert-butoxycarbonyl or benzyloxycarbonyl.

The ester (LI) may be treated with a) for the case where R₂₄ is OH, NR₇, or SH, (LII) in the presence of a base such as sodium hydride or potassium carbonate in a suitable solvent such as DMF or THF , or b) for the case where R₂ is OH or NR₇, (LIII) in the presence of a dehydrating agent such as EDC in the presence of HOBt and NMM in a solvent such as DMF or dichloromethane, optionally in the presence of DMAP, to provide the intermediate of formula (LIV). Removal of RPG₃, by hydrogenation in the presence of palladium on carbon where RPG₃ is benzyloxycarbonyl, affords (XXXIX). Alternately, where RPG₃ is tert- butoxycarbonyl, RPG₃ may be removed by treatment with TFA to afford (XXXIX). Reaction scheme 10 depicts an alternate preparation of an intermediate of general formula (XXXIX).

Reaction Scheme 10

XXXIX

R_3ιR₄, R₇, E], E₃, and E₅ are as defined for general formula (II).

RPG₂ is defined as for reaction scheme 6.

R₂₂ is defined as for reaction scheme 7. RPG₃ is defined as for reaction scheme 9.

The thiol (LVl) may be oxidized to the disulfide (LV) by treatment with a mild base such as TEA and oxygen or air. Either the thiol (LVl) or the disulfide (LV) may be converted to the sulfonyl chloride (LVII) by treatment with chlorine gas in tetrachloromethane.

Treatment of the sulfonyl chloride (LVII) with an amine (LVIII) in the presence of a tertiary amine base such as TEA or NMM affords (LIX). Removal of RPG₃, by hydrogenation in the presence of palladium on carbon where RPG₃ is benzyloxycarbonyl, affords (XXXIX). Alternately, where RPG₃ is tert-butoxycarbonyl, RPG₃ may be removed by freatment with TFA to afford (XXXIX).

Reaction scheme 11 depicts an alternate preparation of an intermediate of general formula (XXXIX).

Reaction Scheme 11

XXXIX

R₃, R₄, R₇, Ei, E₃, and E₅ are as defined for general formula (II). RPG₂ is defined as for reaction scheme 6. R₂₂ is defined as for reaction scheme 7. RPG₃ is defined as for reaction scheme 9.

Treatment of (LX) with the amine (LVIII) and a coupling reagent such as EDC or carbonyldiimidazole in the presence or absence of HOBt, in the presence of a tertiary amine base such as NMM in a solvent such as DMF affords (LXI). Removal of the RPG₃ protecting group as for reaction scheme 10 gives the amine (XXXIX)

Reaction Scheme 12 depicts an alternate preparation of an intermediate of general formula (XXXIX). Reaction Scheme 12

LXV

LXVI

LXVII

¹ "E

I ²

^ , XXXIX HN ³

I

E_c

R₃, R₄, R₇, Ei, E₂, E₃, and E₅ are as defined for general formula (II).

RPG₂ is defined as for reaction scheme 6.

R₂₂ is defined as for reaction scheme 7.

R₂₅ is alkyl, alkenyl, alkynyl, cycloalkyl, or hydrogen.

R₂₆ and R₂₇ are, independently, alkyl, alkenyl, or alkynyl.

R₂₈ is O or NH. R₂₅ and R₂₇ may be taken together to constitute a five to ten - membered ring. R₂₆ and R₂₇ may be taken together to constitute a five to ten - membered ring. The acid (LXII) is treated with trifluoroacetic anhydride and TFA to afford the trifluoroacetamide, which is then treated with the bromide (LXIII) and a base such as potassium carbonate in a solvent such as DMF to provide the ester (LXIV). (LXIV) is treated with LDA and aluminum triisopropoxide in the presence of quinidine or quinine in a solvent such as THF at a temperature of from -78 °C to 0 °C to afford (LXV) with a high degree of asymmetric induction. (LXV) is subjected to hydrolysis with aqueous base and the resulting amine is protected with RPG₂-C1 (where RPG₂ is benzyloxycarbonyl) or (RPG₂)₂0 (where RPG₂ is tert-butoxycarbonyl) and aqueous base. (LXVI) is then treated with R₂₂-Br and potassium carbonate in a solvent such as DMF to afford (LXVII). Alternately (LXVII) where R₂₂ is tert-butyl may be prepared by treatment with dimefhylformamide di-tert-butyl acetal. (LXVII) may be treated with ozone in dichloromethane or dichloromethane MeOH, followed by reduction with, for example, dimethyl sulfide to afford the carbonyl compound (LXVIII). (LXVIII) may be reduced with sodium borohydride to afford the alcohol (LXX) (where R₂₈ is O), which may be treated with methanesulfonyl chloride in pyridine to afford the methanesulfonate. The methanesulfonate may be then treated with sodium azide in a solvent such as DMF at a temperature of from 25 °C to 120 °C to afford the azide, which may be reduced with, for example, palladium and hydrogen gas to provide (LXX) where R₂₈ is NH. The olefin in (LXVII) may be hydroborated with, for example, tert-hexylborane and the intermediate oxidized with alkaline hydrogen peroxide to afford (LXIX) where R₂₈ is O. R₂₈ may be converted to NH as described above. R₂₈ may be further manipulated to afford the intermediate of general structure (XXXIX). Selection of R₂₂ as tert-butyl and RPG₂ as benzyloxycarbonyl is optimal for the preparation of (XXXIX) according to reaction scheme 12. Reaction scheme 13 depicts an alternate preparation of an intermediate of general formula (VI).

Reaction Scherre 13

VI

R₃, }, R₅, and R₆ are as defined for general formula (II).

R₂₉ is alkylene, alkenylene, alkynylene, cycloalkylene, cycloalkenylene, heterocyclylene, arylene, or heteroarylene.

The amino alcohol (LXXI) is treated with phthalic anhydride in a solvent such as toluene at a temperature of from 25 °C to 120 °C, or with N-ethoxycarbonylphthalimide and sodium bicarbonate at a temperature of from - 20 °C to 45 °C, followed by oxidation of the resulting phthalimido alcohol with an oxidizing agent such as pyridinium chlorochromate to provide the aldehyde (LXXII). Treatment of (LXXII) with tπmethylsilyl cyanide and phenylglycinol affords (LXXIII). Use of enantiopure phenylglycinol in this operation may induce chirahty in (LXXIIII), which may be preserved in the subsequent steps of reaction scheme 13. Treatment of (LXXIII) with 12 N HCl at a temperature of 25 °C to 70 °C is followed by treatment with hydrazine and acidification with 1 N HCl. The product is treated in a solvent such as MeOH with palladium hydroxide on carbon under 60 psi of hydrogen pressure at a temperature of from 25 °C to 80 °C, followed by treatment with di-tert-butyl dicarbonate and aqueous sodium hydroxide to afford (LXXIV) after acidification. Treatment of (LXXIV) with the amme (XXXVII) and a dehydrating agent such as EDC in the presence of HOBt in a solvent such as DMF at a temperature of 0 °C to 25 °C, followed by treatment with HCl m a solvent such as dichloromethane or dioxane affords (LXXV). Treatment of (LXXV) with N-ethoxycarbonylphthahmide in a solvent such as DMF with TEA at a temperature of -20 °C, followed by treatment of the product with di-tert-butyl dicarbonate and DMAP a solvent such as dichloromethane affords (LXXVI). (LXXVI) may be treated with hydrazine in a solvent such as MeOH or ethanol to provide (LXXVII). (LXXVII) may be manipulated (amidmation, nitration) as descπbed in previous reaction schemes to afford an intermediate of formula (VI).

PHARMACEUTICAL FORMULATION AND DOSES

The compounds of the present invention can be administered in such oral (including buccal and sublmgual) dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups and emulsions. Likewise, they may also be administered in nasal, ophthalmic, otic, rectal, topical, intravenous (both bolus and infusion), mtrapeπtoneal, mtraarticular, subcutaneous or intramuscular inhalation or insufflation form, all using forms well known to those of ordinary skill m the pharmaceutical arts. The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.

Oral dosages of the present invention, when used for the indicated effects, will range between about 0.1 to 2000 mg/kg of body weight per day, and particularly 1 to 100 mg/kg of body weight per day. Oral dosage units will generally be administered in the range of from 1 to about 250 mg and more preferably from about 25 to 250 mg. The daily dosage for a 70 kg mammal will generally be in the range of about 10 mg to 5 grams of a compound of formula I or II.

While the dosage to be administered is based on the usual conditions such as the physical condition of the patient, age, body weight, past medical history, route of administrations, severity of the conditions and the like, it is generally preferred for oral administration to administer to a human. In some cases, a lower dose is sufficient and, in some cases, a higher dose or more doses may be necessary. Topical application similarly may be once or more than once per day depending upon the usual medical considerations. Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

In the methods of the present invention, the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present.

Capsules are made by preparing a powder mixture as described above, and filling formed gelatin sheaths. Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be added to the powder mixture before the filling operation. A disintegrating or solubilizing agent such as agar-agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.

Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium algmate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentomte, xanthan gum and the like. Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and dismtegrant and pressing into tablets. A powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an a ginate, gelatin, or polyvinyl pyrrohdone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentomte, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen. As an alternative to granulating, the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules. The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of steaπc acid, a stearate salt, talc or mineral oil. The lubricated mixture is then compressed into tablets. The compounds of the present invention can also be combined with free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps. A clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.

Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound m a non-toxic vehicle. Solubihzers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil or saccharin, and the like can also be added.

Where appropriate, dosage unit formulations for oral administration can be microencapsulated. The formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.

The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles Liposomes can be formed from a variety of phosphohpids, such as cholesterol, stearylamme or phosphatidylcholmes.

Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrohdone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyefhylaspartamidephenol, or polyethyleneoxidepolylysme substituted with palmitoyl residues Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful m achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

The present invention includes pharmaceutical compositions containing 0 1 to 99.5%, more particularly, 0.5 to 90% of a compound of the formula (II) in combination with a pharmaceutically acceptable carrier. Parenteral administration can be effected by utilizing liquid dosage unit forms such as sterile solutions and suspensions intended for subcutaneous, intramuscular, intrathecal, lntrarteπal or intravenous injection. These are prepared by suspending or dissolving a measured amount of the compound in a non-toxic liquid vehicle suitable for injection such as aqueous oleaginous medium and sterilizing the suspension or solution.

Alternatively, a measured amount of the compound is placed m a vial and the vial and its contents are sterilized and sealed. An accompanying vial or vehicle can be provided for mixing prior to administration. Non- toxic salts and salt solutions can be added to render the injection lsotonic. Stabilizers, preservations and emulsifiers can also be added.

Rectal administration can be effected utilizing suppositories in which the compound is admixed with low-melting water-soluble or insoluble solids such as polyethylene glycol, cocoa butter, higher ester as for example flavored aqueous solution, while elixirs are prepared through myπstyl palmitate or mixtures thereof.

Topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients m ointments and creams. The formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.

For administration by inhalation the compounds according to the invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotefrafluoroethane, tetrafluoroethane, heptafluoropropane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

The preferred pharmaceutical compositions are those in a form suitable for oral administration, such as tablets and liquids and the like and topical formulations.

EXAMPLES

The following examples are illustrative embodiments of the invention, not limiting the scope of the invention in any way. Reagents are commercially available or are prepared according to procedures in the literature.

Example 1; (2R,3S)-3-(Formyl-hydroxyamino)-2-(2-methyl-l-propyl)hexanoic Acid \(1S)- 4-(nifroimino-amino)methylamino- 1 -( 1 ,3-thiazol-2-ylcarbamoyl)- 1 -butyljamide

Example la; Ethyl (3R)-3-Hydroxyhexanoate and Methyl (3R)-3-Hydroxyhexanoate

Ethyl butyrylacetate (50.0 g, 316 mmol) is stirred in 75 mL of absolute ethanol as [RuCl₂(B_NAP)]₂ ^»NEt₃ (0.139 g, 0.158 mmol) is added along with 2 N hydrochloric acid (0.158 mL, 0.316 mmol). The mixture is placed on a pressure hydrogenation apparatus and degassed by evacuating and filling with nitrogen several times. The vessel is then pressurized with hydrogen to 65 psi. The reaction is heated to 70 °C for 36 h and then is allowed to cool to 25 °C. The resulting reddish brown solution is concentrated under reduced pressure and the product distilled (40-50 °C, 200 millitorr) to give a clear oil (50.0 g, 99% yield, >99% enantiomeric excess determined by chiral analytical HPLC).

Η NMR (400 MHz, CDC1₃) δ 4.17 (q, 2H), 4.01 (m, IH), 2.95 (d, IH), 2.47 (dd, IH), 2.40 (dd, IH), 1.58-1.38 (m, 4H), 1.38 (t, 3H), 0.94 (t, 3H) ppm.

Methyl (3R)-3-hydroxyhexanoate is prepared in the same manner described above in methanol employing methyl butyrylacetate as the starting ketoester. The enantiomeric excess is 99% as determined by chiral analytical HPLC methods.

Η NMR (300 MHz, CDC1₃) δ 4.04 (m, IH), 3.72 (s, 3H), 2.87 (d, IH), 2.50 (dd, IH), 2.46 (dd, IH), 1.58-1.38 (m, 4H), 0.94 (t, 3H) ppm.

Example lb; Methyl (2R,3R)-2-(2-Methyl-2-propene-l-yl)-3-hydroxyhexanoate

To a stirred solution of diisopropylamine (19.4 mL, 139 mmol) in 70 mL of THF at - 78 °C is added dropwise 86.6 mL (139 mmol) of 1.6 M n-butyllithium in hexanes over 15 min. After 1 h, a solution of methyl (3R)-3-hydroxyhexanoate (9.2 g, 63 mmol) in 10 mL of THF is added dropwise over several minutes. The reaction mixture is stirred 1 h, then freated with a solution of 3-bromo-2-methyl-l-propene (7.6 mL, 75.6 mmol) in 10 mL of HMPA and is allowed to stand at -20 °C overnight. The reaction mixture is poured into ice-cold 1 N hydrochloric acid (300 mL) and extracted with two 200 - mL portions of EtOAc. The combined organic layers are washed with two 100 - mL portions of saturated aqueous sodium chloride, dried over sodium sulfate, and filtered. The solvents are removed under reduced pressure. Purification by flash chromatography on silica gel eluting with 10% EtOAc - hexanes affords 7 g (55%) of methyl (2R,3R)-2-(2-methyl-2-propene-l-yl)-3- hydroxyhexanoate as an oil.

TLC R_f (hexanes - EtOAc, 1 :1) 0.75.

'H NMR (300 MHz, CDC1₃) δ 4.82 (s, IH), 4.75 (s, IH), 3.70 (s, 3H), 3.68 (m, IH), 2.70 (m,

IH), 2.50 (m, IH), 2.35 (dd, IH), 1.75 (s, 3H), 1.60-1.65 (m, 4H), 0.95 (t, 3H) ppm.

Example lc; Methyl (2R,3R)-2-(2-Methyl-l-propyl)-3-hydroxyhexanoate

A mixture of methyl (2R,3R)-2-(2-methyl-2-propene-l-yl)-3-hydroxyhexanoate (7 g,

34.6 mmol) and 1.7 g of 5% palladium on carbon (50 wt. % water content) in 50 mL of MeOH is stirred overnight under hydrogen gas at 1 atmosphere pressure. Filtration and concentration of the filtrate under reduced pressure affords 6.5 g (93%) of methyl (2R,3R)-2-

(2-methyl-l-propyl)-3-hydroxyhexanoate as an oil.

TLC R_f (hexanes - EtOAc, 1 :1) 0.75.

Η NMR (300 MHz, CDC1₃) δ 3.75 (s, 3H), 3.65 (m, IH), 2.57 (m, IH), 2.10 (bs, IH), 1.80- 1.23 (m, 7H), 0.90 (m, 9H) ppm.

Example Id; (2R,3R)-2-(2-Methyl-l-propyl)-3-hydroxyhexanoic Acid

A solution of methyl (2R,3R)-2-(2-methyl-l-propyl)-3-hydroxyhexanoate (6.5 g, 31.9 mmol) in 100 mL of water - MeOH - THF (1 :1 :4) is treated with lithium hydroxide monohydrate (1.6 g, 38 mmol) and stirred overnight. The reaction mixture is acidified to pH 2 using 1 M aqueous sodium hydrogen sulfate and extracted with two 100 - mL portions of EtOAc. The combined organic layers are washed with two 25 - mL portions of saturated aqueous sodium chloride, dried over sodium sulfate and filtered, and the solvents are removed under reduced pressure. Purification by flash chromatography on silica gel eluting with 10%

EtOAc - hexanes affords 6.0 g (100%) of (2R,3R)-2-(2-methyl-l-propyl)-3-hydroxyhexanoιc acid as a gum.

Η NMR (300 MHz, CDC1₃) δ 3.65 (m, IH), 2.57 (m, IH), 1.80-1.30 (m, 7H), 0.95 (m, 9H) ppm.

Example le; (2R,3R)-2-(2-Methyl-l-propyl)-3-hydroxyhexanoιc Acid 2- Tetrahydropyranyloxyamide

To a stirred solution of (2R,3R)-2-(2 -methyl- l-propyl)-3-hydroxyhexanoιc acid (6.0 g, 32.3 mmol) m 33 mL of dichloromethane at 0 °C is added 2-tetrahydropyranyloxyamιne (7.70 g, 65.8 mmol) followed by EDC (7.50 g, 394 mmol). The reaction mixture is allowed to warm to 25 °C, stirred 12 h, then diluted with 100 mL of EtOAc and washed successively with 50 mL each of water, 1 M aqueous sodium bisulfate solution, saturated aqueous sodium bicarbonate and saturated aqueous sodium chloride The combined organic layers are dried over sodium sulfate and filtered, and the solvents are removed under reduced pressure. Purification by flash chromatography on silica gel elutmg with 10% EtOAc - hexanes affords 9.0 g (97%) of (2R,3R)-2-(2-methyl-l-propyl)-3-hydroxyhexanoιc acid 2- tefrahydropyranyloxyamide as a gum. TLC R_f (hexanes - EtOAc, 1:1) 0.60. Η NMR (300 MHz, CDC1₃) δ 8.90 (d, IH), 5 00 (2s, IH), 4.00 (m, IH), 3.62 (m, 2H), 3.01 (t, IH), 2.21 (m, IH), 1.90-1.30 (m, 13H), 0.92 (m, 9H) ppm. Example 1 f; (3R,4S)-3 -(2-Methyl- 1 -propyl)-4-propyl- 1 -(2-tetrahydropyranyloxy)azetιdm-2- one

To a stirred solution of (2R,3R)-2-(2 -methyl- l-propyl)-3-hydroxyhexanoιc acid 2- tefrahydropyranyloxyamide (9.0 g, 31.3 mmol) m 50 mL of anhydrous pyridme at 0 °C is added methanesulfonyl chloride (2.9 mL, 37.6 mmol). The reaction mixture is allowed to stand at 5 °C overnight and the pyridme is removed under reduced pressure. The resulting gum is dissolved m EtOAc (200 mL) and washed successively with 50 mL each of ice-cold 0.1 N hydrochloric acid, dilute aqueous sodium carbonate, and saturated aqueous sodium chloride. The combined organic extracts are dried over sodium sulfate and filtered, and the solvents are removed under reduced pressure affording the methanesulfonate as an off-white solid (11.6 g, 98%) which is used without further purification. TLC R_f (hexanes - EtOAc, 1 :1) 0.75. Η NMR (300 MHz, CDC1₃) δ 5.00 (m, IH), 4.81 (m, IH), 4.00 (m, IH), 3.60 (bt, IH), 3.05 (s, 3H), 2.76-2.60 (m, IH), 1.92-1.11 (m, 13H), 0.91 (m, 9H) ppm.

A mixture of powdered potassium carbonate (15.0 g, 109 mmol) in 200 mL of acetone is refluxed for 0.5 h then treated with a solution of the above methanesulfonate in 100 mL of acetone and refluxed for an additional 48 h. The resulting slurry is filtered to remove salts and the filtrate is concentrated under reduced pressure. The crude oil is dissolved in 200 mL of EtOAc and washed successively with 50 mL of water and 50 mL of saturated aqueous sodium chloride and the combined organic extracts are dried over sodium sulfate. Filtration and removal of the solvents under pressure affords 8.2 g (96%) of (3R,4S)-3-(2-methyl-l- propyl)-4-propyl-l-(2-tefrahydropyranyloxy)azetιdm-2-one as a 1 :1 mixture of diastereomers which is used without further purification. TLC R_f (hexanes - EtOAc, 9:1) 0.30.

Η NMR (300 MHz, CDC1₃) δ 5.20 and 5.04 (two m, IH), 4.27 and 4.50 (two dt, IH), 4.01- 3.89 (m, IH), 3.68 (m, IH), 3.05 (m, IH), 1.92-1.30 (m, 13H), 1.00 (m, 9H) ppm. Example 1 g; (2R,3S)-3-(2-Tetrahydropyranyloxyamino)-2-(2-methyl- 1 -propyl)hexanoic Acid

A solution of the lactam (3R,4S)-3-(2-methyl- 1 -propyl)-4-propyl- 1 -(2- tetτahydropyranyloxy)azetidin-2-one (8.2 g, 30.5 mmol) in 90 mL of dioxane is treated with 53 mL of aqueous 3 N aqueous sodium hydroxide and stirred at 25 °C for 24 h. The reaction mixture is adjusted to pH 2 with 1 M aqueous sodium bisulfate and then extracted with two 100 - mL portions of EtOAc. The combined organic exfracts are dried over sodium sulfate and filtered, and the solvents are removed under reduced pressure affording 7.9 g (90%) of crude (2R,3S)-3-(2-tetrahydropyranyloxyamino)-2-(2-methyl-l-propyl)hexanoic acid as a viscous oil which is used without further purification.

Η NMR (300 MHz, CDC1₃) δ 8.80 (bs, IH), 4.85 and 4.75 (two m, IH), 3.95 (m, IH), 3.60 (m, IH), 3.19 and 2.87 (two m, lH), 3.05 (m, IH), 1.95-1.12 (m, 13H), 0.91 (m, 9H) ppm.

Example lh; (2R,3S)-3-(Formyl-2-tefrahydropyranyloxyamino)-2-(2-methyl-l- propyl)hexanoic Acid

A solution of (2R,3S)-3-(2-tetrahydropyranyloxyamino)-2-(2-methyl-l- propyl)hexanoic acid (7.90 g, 27.5 mmol) in 100 mL of anhydrous pyridine is cooled to 0 °C and treated with formic acetic anhydride (4.0 mL, 46 mmol). The reaction mixture is allowed to warm to 25 °C, stirred for 6 h, and then concentrated to dryness under reduced pressure. The resulting gum is dissolved in 150 mL of EtOAc and washed successively with two 50 - mL portions of 1 M aqueous sodium bisulfate and two 50 - mL portions of saturated aqueous sodium chloride. The combined organic exfracts are dried over sodium sulfate and filtered, and the solvents are removed under reduced pressure affording 8.67 g (99%) of (2R,3S)-3- (formyl-2-tefrahydropyranyloxyamino)-2-(2-methyl- 1 -propyl)hexanoic acid obtained as a viscous oil.

Η NMR (300 MHz, CDC1₃) δ 8.68 and 8.56 (d and s, IH), 5.07 and 4.81 (two s, IH), 4.40 (m, IH), 4.00 (m, IH), 3.62 (m, IH), 2.90 and 2.72 (two t, IH), 2.00-1.20 (m, 13H), 0.98 (m, 9H) ppm.

Example 1 i; (2S)-2-tert-Butoxycarbonylamino-5-(nitroimino-amino)methylaminopentanoic Acid l,3-Thiazol-2-ylamide

To a stirred solution of (2S)-2-tert-butoxycarbonylamino-5-(nitroimino- amino)methylaminopentanoic acid (5.00 g, 15.6 mmol) and 2-aminothiazole (1.72 g, 17.2 mmol) in DMF (16 mL) is added EDC (3.30 g, 17.2 mmol). The solution is allowed to stir for 4 h then added to half-saturated aqueous sodium chloride solution and extracted with EtOAc. The combined organic extracts are washed with 1 N sodium bisulfate, 5% aqueous sodium bicarbonate, saturated aqueous sodium chloride, and dried over magnesium sulfate. Concentration in vacuo provides (2S)-2-tert-butoxycarbonylamino-5-(nitroimino- amino)methylaminopentanoic acid l,3-thiazol-2-ylamide as a solid (2.28 g, 36%). Η NMR (CD₃OD, 400 MHz) δ 7.42 (d, IH), 7.10 (d, IH), 4.31 (m, IH), 3.29 (m, 2H), 1.85 (m, IH), 1.71 (m, 2H), 1.41 (s, 9H), 1.33 (m, IH) ppm.

Example lj; (2S)-2-Amino-5-(nitroimino-amino)methylaminopentanoic Acid l,3-Thiazol-2- ylamide Hydrochloride

(2S)-2-tert-Butoxycarbonylamino-5-(nitroimino-amino)methylaminopentanoic acid 1,3- thiazol-2-ylamide (2.28 g, 5.68 mmol) is dissolved in 5 mL THF and 5 mL 4 N HCl in dioxane. After 3 h, dichloromethane is added and the mixture is filtered.. The semisolid is collected and is freated with methanol - toluene and concentrated in vacuo; this process is repeated several times to afford 1.63 g of (2S)-2-amιno-5-(nιtroιmmo- ammo)methylammopentanoιc acid l,3-thιazol-2-ylamιde hydrochloride as a solid. 'H NMR (DMSO-d₆, 300 MHz) δ 8.58 (bs, 4H), 7.99 (bs, IH), 7.52 (d, IH), 7.31 (d, IH), 6.4- 5.9 (bs, 2H), 4.08 (m, IH), 3.17 (bs, 2H), 1.83 (m, 2H), 1.53 (m, 2H) ppm. ESI-MS m/z 302 (M+H)⁺

Example Ik; (2R,3S)-3-(Formyl-2-tetrahydropyranyloxyamιno)-2-(2-methyl-l- propyl)hexanoιc Acid [( 1 S)-4-(nιtroιmmo-amιno)methylamιno- 1 -( 1 ,3 -thιazol-2- ylcarbamoyl)- 1 -butyl] amide

To a 0 °C solution of (2R,3S)-3-(formyl-2-tefrahydropyranyloxyamιno)-2-(2-methyl-l- propyl)hexanoιc acid (172 mg, 0.546 mmol) m 1 mL DMF is added diethyl cyanophosphonate (98 mg, 0.60 mmol) followed by NMM (61 mg, 0 60 mmol). Stirring is continued for 30 min at 0 °C. (2>S)-2-Amιno-5-(nιfroιmιno-amιno)methylamιnopentanoιc acid l,3-thιazol-2-ylamιde hydrochloride (203 mg, 0.60 mmol) is added followed by additional NMM (122 mg, 1.20 mmol). The mixture is heated at 40 °C for 16 h then allowed to cool to 25 °C. The reaction mixture is added to half-saturated aqueous sodium chloride and extracted with 1 : 1 EtOAc - diethyl ether. The combined organic layers are washed with pH 4.3 phosphate buffer, 5% aqueous sodium bicarbonate, saturated aqueous sodium chloride, and dried over magnesium sulfate Concentration and chromatography on silica gel (5% methanol - dichloromethane) provides 166 mg of (2R,3S)-3-(formyl-2-tetrahydropyranyloxyamιno)-2- (2-methyl- 1 -propyl)hexanoιc Acid [( 1 S)-4-(nιfroιmιno-amιno)methylammo- 1 -( 1 ,3-thιazol-2- ylcarbamoyl)-l -butyl] amide as a foam ESI-MS m/z 599 (M+H)⁺, 621 (M+Na)⁺.

Example 1; (2R,3S)-3-(Formyl-hydroxyamιno)-2-(2-methyl-l-propyl)hexanoιc Acid [(15)-4-

(nιtroιmmo-ammo)methylamιno- 1 -(1 ,3-thιazol-2-ylcarbamoyl)- 1 -butyl]amιde (2R,3S)-3-(Formyl-2-tetrahydropyranyloxyamιno)-2-(2-methyl- 1 -propyl)hexanoιc acid [( 1 S)-4-(nιtroιmιno-ammo)methylammo- 1 -( 1 ,3-thιazol-2-ylcarbamoyl)- 1 -butyl]amιde ( 166 mg) is dissolved in 2 mL 80% acetic acid and heated at 40 °C for 20 h. Concentration in vacuo and frituration in dichloromethane - ether provides (2R,3S)-3-(formyl-hydroxyamιno)- 2-(2-methyl- 1 -propyl)hexanoιc acid [( 1 S)-4-(nιfroιmιno-ammo)methylammo- 1 -( 1 ,3-thιazol- 2-ylcarbamoyl)-l-butyl]amιde as a solid (106 mg, 74%). Mp 130-136 °C Anal. Calcd. for C₂₀H₃₄N₈O₆S: C, 46.68; H, 6.66; N, 21.78; S, 6.23; Found. C, 46.45; H, 6.75; N, 21.60; S, 6.14.

Example 2; (2R,35)-3-(Formyl-hydroxyamιno)-2-(cyclohexylmethyl)hexanoιc Acid \(lS)-4- (nιtroιmmo-amιno)methylamιno- 1 -( 1 ,3-thιazol-2-ylcarbamoyl)- 1 -butyl]amιde

Example 2a; Ethyl (2R,3R)-2-Cyclohexylmethyl-3-hydroxyhexanoate

Dπsopropylamme (5.89 mL, 44.9 mmol) is dissolved in 30 mL of anhydrous THF and chilled to 0 °C. n-Butyllithium (16.5 mL of a 2.5 M solution in hexanes, 41.2 mmol) is added dropwise over 10 min and the resulting pale yellow solution cooled to -78 °C. A 15 - mL THF solution of ethyl (3R)-3-hydroxyhexanoate (3.00 g, 18.7 mmol) is added over 10 mm and stirred for 30 mm. Cyclohexylmethyl iodide (6.29 g, 28.05 mmol) is dissolved m 20 mL of a 1 : 1 THF/HMPA solution and added to the dianion at -78 °C dropwise. The resulting solution is allowed to warm slowly to 0 °C over 3 h. After stirring overnight at 4 °C 250 mL of a 5% aqueous citric acid solution is added and the mixture is extracted with two 250 - mL portions of ether. The combined organics are washed with saturated aqueous sodium chloride, dried over sodium sulfate, and concentrated in vacuo. The crude product is chromatographed on silica gel (elution with 25% EtOAc - hexanes) to provide ethyl (2R,3R)-2-cyclohexylmethyl-3-hydroxyhexanoate (1.44 g, 30% yield) as an oil. Η NMR (300 MHz, CDC1₃) δ 4.15 (q, 2H), 3.65 (m, IH), 2.60 (m, IH), 2.40 (d, IH), 1.96- 0.94 (m, 23H) ppm.

Example 2b; Methyl (2R,3R)-2-Benzyl-3-hydroxyhexanoate

Diisopropylamine (8.61 mL, 65.7 mmol) is dissolved in 40 mL of anhydrous THF and chilled to 0 °C. n-Butyllithium (30.1 mL of a 2.0M solution in hexanes, 60.2 mmol) is added dropwise over 10 min and the resulting pale yellow solution cooled to -78 °C. A 15 - mL THF solution of methyl (3R)-3-hydroxyhexanoate (4.00 g, 27.4 mmol) is added over 10 min and stirred for 30 min. Benzyl bromide (3.60 mL, 30.1 mmol) is dissolved in 12 mL of a 1 : 1 THF HMPA solution and added at -78 °C dropwise. The resulting solution is allowed to warm slowly to 0 °C over 3h. Aqueous 5% citric acid solution (250 mL) is added and the organics are extracted with two 250 - mL portions of ether. The combined organics are washed with saturated aqueous sodium chloride. Drying over sodium sulfate and concentration is followed by which is chromatography on silica gel (elution with 25% EtOAc - hexanes) giving methyl (2R,3R)-2-benzyl-3-hydroxyhexanoate as an oil (3.03 g, 64% yield). Η NMR (300 MHz, CDC1₃) δ 7.30 (m, 2H), 7.18 (m, 3H), 3.65 (m, IH), 3.62 (s, 3H), 3.02 (m, 2H), 2.75 (m, IH), 2.55 (d, IH), 1.50-1.35 (m, 4H), 0.90 (t, 3H) ppm.

Example 2c; Methyl (2R,3R)-2-Cyclohexylmethyl-3-hydroxyhexanoate Methyl (2R,3R)-2-benzyl-3-hydroxyhexanoate (3.35 g, 14.2 mmol) is dissolved in 35 mL of MeOH. Under an argon atmosphere 1.00 g of 5% rhodium on carbon is added. The reaction vessel is evacuated and refilled with hydrogen several times and then pressurized with hydrogen to 65 psi. After 8 h the reaction vessel is evacuated and refilled with nitrogen. The solution is filtered and the filtrate concentrated in vacuo giving methyl (2R,3R)-2- cyclohexylmethyl-3-hydroxyhexanoate as an oil (3.44 g, 99% yield). ^■H NMR (300 MHz, CDC1₃) δ 3.72 (s, 3H), 3.65 (m, IH), 2.60 (m, IH), 2.40 (d, IH), 1.96- 0.94 (m, 23H) ppm.

Example 2d; (2R,3R)-2-Cyclohexylmethyl-3-hydroxyhexanoιc Acid

Methyl (2R,3R)-2-cyclohexylmethyl-3-hydroxyhexanoate (3.44 g, 14.2 mmol) is dissolved in 3:1 :1 THF - MeOH - H₂0 (35 mL). To this is added lithium hydroxide monohydrate (1.79 g, 42.6 mmol). The reaction mixture is stirred for 18 h at 25 °C and the mixture is then extracted with ether. The aqueous layer is acidified with solid sodium bisulfate and then extracted with two 250 - mL portions of ether. The combined organics are washed with saturated aqueous sodium chloride, dried over sodium sulfate, and concentrated under reduced pressure to afford (2R,3R)-2-cyclohexylmethyl-3-hydroxyhexanoιc acid as a solid (3.05 g, 96% yield).

Η NMR (300 MHz, CDC1₃) δ 3.67 (m, IH), 2.60 (m, IH), 1.85-0.94 (m, 20H) ppm.

Example 2e; (2R,3R)-2-Cyclohexylmethyl-3-hydroxyhexanoιc Acid 2- Tetrahydropyranyloxyamide

(2R,3R)-2-Cyclohexylmethyl-3-hydroxyhexanoιc acid (3.00 g, 13.1 mmol) is dissolved m 30 mL of anhydrous dichloromethane. EDC (2.77 g, 14.5 mmol) is added followed by 2-tetrahydropyranyloxyamine (3.08 g, 26.3 mmol). The reaction is stirred at 25 °C for 8 h and is then poured into 200 mL of 1 M hydrochloric acid. The mixture is extracted with two 250 - mL portions of dichloromethane. The combined organics are then washed with saturated aqueous sodium chloride, dried over sodium sulfate, and concentrated under reduced pressure to afford (2R,3R)-2-cyclohexylmethyl-3-hydroxyhexanoic acid 2- tetrahydropyranyloxyamide as a foam (3.60 g, 84% yield).

'HNMR (300 MHz, CDC1₃) δ 8.45 (two s, IH), 4.96 (two s, IH), 3.95 (m, IH), 3.64 (m, 2H), 2.75 (two d, IH), 2.20 (m, IH), 1.83-0.92 (m, 26H) ppm.

Example 2f; (3R,4S)-3-Cyclohexylmethyl-4-propyl-l-(2-tetrahydropyranyloxy)azetidin-2-one

(2R,3R)-2-Cyclohexylmethyl-3-hydroxyhexanoic acid 2-tefrahydropyranyloxyamide (3.60 g, 11.0 mmol) is dissolved in 15 mL of pyridine and cooled to 0 °C. Methanesulfonyl chloride (0.98 mL, 12.6 mmol) is added dropwise and the reaction is stirred at 0 °C for 6 h. The reaction is poured into 20 mL of ice cold 2 M hydrochloric acid and the mixture extracted with two 25 - mL portions of EtOAc. The combined organics are washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, and concentrated under reduced pressure to afford the methanesulfonate which is used with no further purification (4.00 g, 90% yield). Η NMR (300 MHz, CDC1₃) δ 8.34 and 8.27 (two s, IH), 4.95 (m, IH), 4.77 (m, IH), 3.94 (m, IH), 3.64 (m, IH), 3.01 (s, 3H), 2.55 (m, IH), 1.85-0.95 (m, 26H) ppm.

Potassium carbonate (4.09 g, 29.6 mmol) is added to 30 mL of acetone and the suspension is refluxed for 1 h. The above crude methanesulfonate (4.00 g, 9.86 mmol) is dissolved in 10 mL acetone and added. The resulting thick slurry continued to reflux for 16 h and is then cooled to 25 °C. The mixture is filtered and the filtrate is concentrated under reduced pressure giving (3R,4S)-3-cyclohexylmethyl-4-propyl-l-(2- tetrahydropyranyloxy)azetidin-2-one as an oil (2.28 g, 75% yield). Η NMR (300 MHz, CDC1₃) δ 5.18 and 5.01 (two s, IH), 4.23 and 4.14 (two m, IH), 3.90 (m, IH), 3.63 (m, IH), 3.02 (m, IH), 1.85-0.93 (m, 26H) ppm.

Example 2g; (2R,3S)-3-(2-Tetrahydropyranyloxyamino)-2-(cyclohexylmethyl)hexanoic Acid

(3R,4S)-3-Cyclohexylmethyl-4-propyl-l-(2-tefrahydropyranyloxy)azetidin-2-one (2.25 g, 7.27 mmol) is dissolved in 10 mL of 1 ,4-dioxane. 2.5 N Aqueous sodium hydroxide solution (8.73 mL, 21.8 mmol) is added and the reaction stirred for 18 h at 25 °C. The solution is diluted with 50 mL of ether and shaken. The organic phase is discarded and the aqueous layer is acidified with solid sodium bisulfate and then exfracted with two 25 - mL portions of ether. The combined organic phases are dried over sodium sulfate and concentrated in vacuo giving (2R,3S)-3-(2-tetrahydropyranyloxyamino)-2- (cyclohexylmethyl)hexanoic acid as an oil (2.02 g, 85% yield). Η NMR (300 MHz, CDC1₃) δ 4.84 and 4.74 (two s, IH), 4.02 and 3.94 (two m, IH), 3.60 (m, IH), 3.16-3.03 and 2.91 (two m, 2H), 21.84-0.86 (m, 26H) ppm.

Example 2h; (2R,3S)-3-(Formyl-2-tefrahydropyranyloxyamino)-2- (cyclohexylmethyl)hexanoic Acid

(2R,3S)-3-(2-Tetrahydropyranyloxyamino)-2-(cyclohexylmethyl)hexanoic acid (2.00 g, 6.11 mmol) is dissolved in 15 mL of pyridine. Formic acetic anhydride (1.08 mL, 12.2 mmol) is added at 25 °C. The reaction is stirred for an additional 6 h and then is poured into 50 mL of cold 1 M hydrochloric acid. The organics are extracted with two 250 - mL portions of dichloromethane. The combined organic phases are then washed with saturated aqueous sodium chloride, dried over sodium sulfate, and concentrated in vacuo to afford (2R,3S)-3- (formyl-2-tetrahydropyranyloxyamino)-2-(cyclohexylmethyl)hexanoic acid (2.17 g, 100% yield). APCI-MS m/z 378 (M+Na)⁺, 354 (M-H)\

Example 2i; 2R,3S)-3-(Formyl-2-tetrahydropyranyloxyamino)-2-(cyclohexylmethyl)hexanoic Acid [( 1 S)-4-(nitroimino-amino)methylamino- 1 -( 1 ,3-thiazol-2-ylcarbamoyl)- 1 -butyl]amide

To a 0 °C solution of (2R,3S)-3-(formyl-2-tefrahydropyranyloxyamino)-2- (cyclohexylmethyl)hexanoic acid (114 mg, 0.321 mmol) in 1 mL of DMF is added diethyl cyanophosphonate (58 mg, 0.353 mmol) followed by NMM (33 mg). Stirring is continued for 30 min. at 0° C. (2S)-2-Amino-5-(nitroimino-amino)methylaminopentanoic acid 1,3- fhiazol-2-ylamide hydrochloride (144 mg, 0.385 mmol) is added followed by additional

NMM (97 mg). The mixture is heated at 40 °C for 16 h then is allowed to cool to 25 °C. The reaction mixture is added to half-saturated aqueous sodium chloride and extracted with 1 : 1 EtOAc - ether. The combined organic layers are washed with pH 4.3 phosphate buffer, 5% aqueous sodium bicarbonate, saturated aqueous sodium chloride, and dried over magnesium sulfate. Concentration and purification by chromatography on silica gel (elution with 5% methanol in dichloromethane) provided 115 mg of (2R,3S)-3-(formyl-2- tetrahydropyranyloxyamino)-2-(cyclohexylmethyl)hexanoic acid [( 1 S)-4-(nitroimino- amino)methylamino-l-(l,3-thiazol-2-ylcarbamoyl)-l-butyl]amide as a foam. ESI-MS m z 661 (M+Na^.

Example 2; (2R,3S)-3-(Formyl-hydroxyamino)-2-(cyclohexylmethyl)hexanoic Acid [(lS)-4- (Nitroimino-amino)methylamino- 1 -(1 ,3-thiazol-2-ylcarbamoyl)- 1 -butyl]amide

(2R,3S)-3-(Formyl-2-tetrahydropyranyloxyamino)-2-(cyclohexylmethyl)hexanoic acid [(lS)-4-(nitroimino-amino)methylamino-l-(l,3-thiazol-2-ylcarbamoyl)-l-butyl]amide ( 115 mg, 0.180 mmol) is dissolved in 2 mL of 80% acetic acid and heated at 40 °C for 20 h.

Concentration in vacuo and frituration with dichloromethane - ether provided 81 mg of (2R,3S)-3-(formyl-hydroxyamino)-2-(cyclohexylmethyl)hexanoic acid [(lS)-4-(nitroimino- amino)methylamino-l-(l,3-thiazol-2-ylcarbamoyl)-l-butyl]amide as a solid. Mp l80 °C (dec)

Anal: Calcd. for C₂₃H₃₈N₈0₆S 0.25 H₂0: C, 49.40; H, 6.94; N, 20.04; S, 5.73. Found: C, 49.38; H, 6.96; N, 19.75; S, 5.57.

Example 3; (2R,3S)-3-(Foιmyl-hydroxyamino)-2-(2-methyl-l-propyl)butanoic Acid [(IS,

2R)-2-Methyl-4-(nitroimino-amino)methylamino-l-(l,3-thiazol-2-ylcarbamoyl)-l- butyl]amide

Example 3a; Methyl (2R,3R)-2-(2-Methyl-2-propen-l-yl)-3-hydroxybutanoate

A solution of 31.1 g (372 mmol) of diisopropylamine in 300 mL of THF is cooled to - 40 °C and treated with 186.2 mL (372 mmol) of 2.0 M n-butyllithium in hexanes. The mixture is stirred at 0 °C for 15 min. The solution is then cooled to -78 °C and freated dropwise with 20 g (170 mmol) of methyl (3R)-3-hydroxybutyrate. This solution is stirred at 0 °C for 45 min, followed by stirring at -78 °C for 15 min. The flask is charged with 25.5 g (342 mmol) of 3-bromo-2 -methyl- 1-propene along with 15 mL of HMPA and stirred for 4 h at -78 °C. The reaction mixture then is allowed to stand at -20 °C for 19 h. The reaction is slowly treated with excess saturated aqueous ammonium chloride over 15 min and the resulting solution is partitioned between ether and 1 N aqueous hydrochloric acid. The organics are dried over magnesium sulfate and concenfrated in vacuo to afford 23.1 g of crude oil. A sample (10 g) of the crude product is chromatographed on silica gel (elution with 4:1 hexanes - EtOAc) to afford 8.1 g (28%) of methyl (2R,3R)-2-(2-methyl-3-propen-l-yl)-3- hydroxybutanoate as an oil. Η NMR (400 MHz, CDC1₃) δ 4.77 (d, 2H), 3.90 (m, IH), 3.69 (s, 3H), 2.68 (m, IH), 2.52- 2.41 (m, 2H), 2.36 (m, IH), 1.5 (s, 3H), 1.22 (s, 3H) ppm. APCI-MS m/z 173 (M+H)⁺.

Example 3b; Methyl (2R,3R)-2-(2-Methyl-l-propyl)-3-hydroxybutanoate

Methyl (2R,3R)-2-(2-methyl-2-propen-l-yl)-3-hydroxybutanoate (8.1 g, 47.1 mmol) in 85 mL of EtOAc is treated with 800 mg of 10% palladium on carbon and the mixture is evacuated and purged with nitrogen. The heterogeneous solution is stirred under 52 psi of hydrogen for 1.5 h. Filtration and concentration of the filtrate in vacuo affords 7.99 g (96%) of methyl (2R,3R)-2-(2-methyl-l-propyl)-3-hydroxybutanoate as an oil.

'H NMR (400 MHz, CDC1₃) δ 3.85 (m, IH), 3.69 (s, 3H), 2.51-2.42 (m, 2H), 1.71-1.62 (m, IH), 1.58-1.48 (m, IH), 1.38-1.30 (m, IH), 1.22 (d, 3H), 0.94-0.86 (dd, 6H) ppm. APCI-MS m/z 175 (M+H)⁺.

Example 3 c; (2R,3R)-2-(2-Methyl-l-propyl)-3-hydroxybutanoic Acid

Methyl (2R,3R)-2-(2-methyl-l-propyl)-3-hydroxybutanoate (7.99 g, 46 mmol) in 50 mL of THF is treated with 50 mL of water containing 3.9 g (92 mmol) of lithium hydroxide monohydrate. The reaction flask is treated with 5.0 mL of MeOH and allowed to stir for 17 h at 25 °C. The mixture is partitioned between water and ether followed by separation of the aqueous layer. The aqueous solution is brought to pH 3 with 6 N aqueous hydrochloric acid and the mixture is extracted with ether. The organic phase is dried over magnesium sulfate and concentrated under reduced pressure to afford 6.6 g (90%) of (2R,3R)-2-(2-methyl-l- propyl)-3-hydroxybutanoic acid.

Η NMR (400 MHz, CDCl₃) δ 3.91 (m, IH), 2.50 (m, IH), 1.75-1.61 (m, 2H), 1.40-1.29 (m, IH), 1.29-1.24 (d, 3H), 0.96 (dd, 6H) ppm. APCI-MS m/z 161 (M+H)⁺.

Example 3d; (2R,3R)-2-(2-Methyl-l-propyl)-3-hydroxyhexanoic Acid 2- Tetrahydropyranyloxyamide

(2R,3R)-2-(2-Methyl-l-propyl)-3-hydroxybutanoic acid (6.6 g, 41.2 mmol) and 5.3 g

(45.3 mmol) of 2-tetrahydropyranyloxyamine are stirred in 60 mL of dichloromethane as 8.7 g (45.3 mmol) of EDC is added. After 4 h at 25 °C the reaction mixture is partitioned between 1 N aqueous hydrochloric acid and dichloromethane and the organics are washed with saturated aqueous sodium bicarbonate. The organics are dried over magnesium sulfate and concenfrated under reduced pressure to afford 5.9 g (55%) of (2R,3R)-2-(2-methyl-l- propyl)-3-hydroxyhexanoic acid 2-tetrahydropyranyloxyamide as an oil. Η NMR (400 MHz, CDC1₃) δ 8.45 (d, IH), 5.0 (d, IH), 3.81-4.00 (m, 2H), 2.05-2.15 (m, IH), 1.45-1.83 (m, 10H), 1.23-1.38 (m, IH), 1.22 (d, 3H), 0.96 (dd, 6H) ppm. APCI-MS m/z 260 (M+H)⁺.

Example 3e; (3R,4S)-3-(2-Methyl-l-propyl)-4-methyl-l-(2-tetrahydropyranyloxy)azetidin-2- one

(2R,3R)-2-(2-Methyl-l-propyl)-3-hydroxyhexanoic acid 2- tefrahydropyranyloxyamide (5.8 g, 22.3 mmol) in 42 mL of dry pyridine is cooled to 0 °C and treated with 2.81 g (24.6 mmol) of methanesulfonyl chloride followed by stirring at 0 °C for 4 h. The reaction mixture is poured into 1 N aqueous hydrochloric acid and extracted with EtOAc. The organics are washed with three portions of saturated aqueous cupπc sulfate. The organic layer is dried over magnesium sulfate and concentrated under reduced pressure to provide 6.1 g of the crude methanesulfonate which is used directly in the next step.

The crude methanesulfonate is stirred in 150 mL of dry acetone and treated with 7.5 g (54.3 mmol) of potassium carbonate. The reaction is stirred at reflux for 17 h and the mixture is then allowed to cool to 25 °C. The mixture is filtered and the filtrate is concentrated to afford an oil (4.5 g) which is chromatographed on silica gel (elution with 4:1 hexanes - EtOAc) to give 3.5 g (65%) of (3R,4S)-3-(2-methyl-l-propyl)-4-methyl-l-(2- tetrahydropyranyloxy)azetιdm-2-one as an oil. Η NMR (400 MHz, CDC1₃) δ 5 10 and 4.97 (two m, IH), 4.18-3.97 (m, 2H), 3.60 (m, IH), 3.03-2.88 (m, IH), 1.82-1.50 (m, 8H), 1.30-1.25 (m, IH), 1.24-1.20 (dd, 3H), 0.95 (dd, 6H) ppm. APCI-MS m/z 242 (M+H)⁺.

Example 3f; (2R,3S)-3-(2-Tetrahydropyranyloxyammo)-2-(2-methyl-l-propyl)butanoιc Acid

(3R,4S)-3-(2-Methyl- 1 -propyl)-4-methyl- 1 -(2-tetrahydropyranyloxy)azetιdιn-2-one (3.5 g, 14.5 mmol) in 30 mL of ethylene glycol dimethyl ether is treated with 20 mL of 2.5 M aqueous sodium hydroxide solution. The mixture is stirred at 25 °C for 16 h and is then brought to pH 3 by addition of saturated aqueous sodium bisulfate solution. The mixture is extracted with ether and the organics are dried over magnesium sulfate and concentrated under reduced pressure to give 3.2 g (84%) of (2R,3S)-3-(2-tetrahydropyranyloxyamιno)-2- (2-methyl-l-propyl)butanoιc acid as an oil. Η NMR (400 MHz, CDC1₃) δ 4.82 and 4.74 (two m, IH), 4.00-3.83 (m, IH), 3.60-3.50 (m, IH), 3.33-3.20 (m, IH), 3.00-2.96 (m, IH), 1.82-1.40 (m, 8H), 1.20-1.08 (m, IH), 1.11-1.05 (dd, 3H), 0.93 (dd, 6H) ppm. APCI-MS m/z 260 (M+H)⁺. Example 3g; N-Trifluoroacetylglycine

A suspension of 100 g (1.33 mol) of glycine in 450 mL of TFA is treated with 385 mL (2.73 mol) of frifluoroacetic anhydride. The mixture is allowed to stir for 1.5 h. The mixture is concentrated in vacuo and is treated with 1 L of 1 : 1 chloroform - hexanes. The slurry is concentrated in vacuo, treated with 1 L of EtOAc, warmed, then allowed to cool to 25 °C and then to 4 °C. The solid is collected and dried to afford 89.21 g of N- trifluoroacetylglycine as a solid. The filtrate is concenfrated in vacuo, treated with EtOAc, warmed, and allowed to cool to 25 °C. Collection of the solid affords a further 58.08 g of N- trifluoroacetylglycine. Η NMR (400 MHz, CDC1₃) δ 12.90 (s, IH), 9.75 (s, IH), 3.81 (s, 2H) ppm.

Example 3h; (2£)-2-Buten-l-yl N-Trifluoroacetylglycinate

A mixture of 143.1 g (836 mmol) of N-trifluoroacetylglycine in 1 L of DMF is chilled to -8 °C as 100 mL (844 mmol) of E-crotyl bromide is added dropwise, followed by addition of 140 mL (937 mmol) of DBU at -5 °C. After 1.5 h at - 5 °C and 2 h at -2 °C the mixture is allowed to warm to 25 °C. The mixture is cooled to 0 °C and 40 mL more DBU is added. After warming to 25 °C the mixture is concentrated in vacuo. 1 L of 1 : 1 ether - water is added. The organic layer is separated, washed with water, 1 N HCl, saturated aqueous sodium bicarbonate, and saturated aqueous sodium chloride. Drying and concentration in vacuo is followed by trituration of the oil with hexanes - EtOAC to provide a solid. Chromatography on silica gel (elution with 3:1 hexanes - EtOAc) affords 49.96 g of (2£ -2-buten-l-yl N-trifluoroacetylglycinate as an oil.

Η NMR (400 MHz, d₆-DMSO) δ 9.87 (bs, IH), 5.75 (m, IH), 5.55 (m, IH), 4.51 (d, 2H), 3.96 (d, 2H), 1.64 (d, 3H) ppm. Example 3ι; (2S,3R)-2-Tπfluoroacetylamιno-3-methyl-4-pentenoιc Acid

A solution of 217 mL (1.04 mol) of hexamethyldisilazane in 400 mL of THF is chilled to - 28 °C and treated with 400 mL (1.0 mol) of 2.5 M n-butylhthium in hexanes. This solution of lithium hexamethyldisilazide is allowed to warm to 25 °C and is then added dropwise to a - 78 °C mixture of 45 g (0.20 mol) of (2£)-2-buten-l-yl N- tπfluoroacetylglycmate , 45 g (0 220 mol) of aluminum friisopropoxide, and 162 g (0.50 mol) of dry qumidme m 1400 mL of THF. The mixture is stirred at - 77 °C for 1 h, then is allowed to warm to 25 °C After 2 d the mixture is treated with 300 mL of ether and 2 L of 1.25 M aqueous potassium bisulfate Additional solid bisulfate is added to adjust pH to 2. The organic phase is separated and the aqueous phase is extracted with ether. The combined organic phases are washed with aqueous potassium bisulfate, then extracted with 10% aqueous sodium bicarbonate. The aqueous phase is carefully acidified with solid sodium bisulfate to pH 1 , then the mixture is extracted with ether. Addition of charcoal to the organic phase, drying over magnesium sulfate, filtration, and concentration in vacuo affords 25.16 g (56%) of (2S,3R)-2-tπfluoroacetylamιno-3-methyl-4-pentenoιc acid as an oil. Η NMR (300 MHz, CDC1₃) δ 9.82 (bs, IH), 6.78 (bd, IH), 5.72 (ddd, IH), 5.19 (m, 2H), 4.68 (dd, IH), 2.84 (m, IH), 1.17 (d, 3H) ppm.

Example 3j; (2S,3R)-2-Benzyloxycarbonylamιno-3-methyl-4-pentenoιc Acid

A mixture of 25.16 g (112 mmol) of (2S,3R)-2-tπfluoroacetylamιno-3-methyl-4- pentenoic acid and 112 mL of 2 N aqueous sodium hydroxide is stirred at 80 °C for 1.5 h. The mixture is then allowed to cool to 25 °C and is further chilled to 0 °C 2 N aqueous sodium hydroxide (112 mL) is added followed by dropwise addition of 18 mL (126 mmol) of benzyl chloroformate. After 45 min at 0 °C and 5 h at 25 °C the mixture is added to 150 mL of water and is treated with aqueous sodium hydroxide until an orange solution resulted. The mixture is extracted with ether. The aqueous phase is acidified with 6 N HCl to pH 1 and is extracted with ether. Drying over magnesium sulfate and concentration in vacuo affords 22.61 g (77%) of (2S,3R)-2-benzyloxycarbonylammo-3-methyl-4-pentenoιc acid as an oil. Η NMR (300 MHz, CDC1₃) δ 8.39 (bs, IH), 7.35 (bs, 5H), 5.71 (ddd, IH), 5.13 (m, 2H), 4.43 (dd, IH), 2.74 (m, IH), 1.10 (d, 3H) ppm. ESI-MS m/z 264 (M+H)\ 286 (M+Na)⁺

Example 3k; tert-Butyl (2S,3R)-2-Benzyloxycarbonylammo-3 -methyl -4-pentenoate

A solution of 20.6 g (78.2 mmol) of (2S,3R)-2-benzyloxycarbonylammo-3-methyl- 4-pentenoιc acid in 156 mL of toluene is heated to 80 °C as 75 mL (313 mmol) of dimethylformamide di-tert-butyl acetal is added. After 45 mm at 80 °C an additional 10 mL of dimethylformamide di-tert-butyl acetal is added and the mixture is allowed to stir at 80 °C for 1 h. The mixture is cooled to 25 °C and ether is added. The mixture is washed with water, 5% aqueous sodium bicarbonate, saturated aqueous sodium chloride, and is dried over magnesium sulfate. Concenfration in vacuo gives 15.49 g (62%) of tert-butyl (2S,3R)-2- benzyloxycarbonylamιno-3-methyl-4-pentenoate as an oil. Η NMR (300 MHz, CDC1₃) δ 7.30 (m, 5H), 5.75 (m, IH), 5.28 (bd, IH), 5.07 (m, 2H), 4.27 (bd, IH), 2.63 (m, IH), 1.44 (s, 9H), 1.04 (d, 3H) ppm.

Example 31; tert-Butyl (2S,3R)-2-benzyloxycarbonylamιno-3-methyl-5-hydroxypentanoate

To a 0 °C solution of 2,3-dιmethyl-2-butene in THF (43.2 mmol, 1.0 M) is added a solution of borane in THF (43.2 mmol, 1.0 M) dropwise over 20 mm. After stirring an additional 60 min at 0 °C, tert-butyl (2S,3R)-2-benzyloxycarbonylamιno-3 -methyl -4- pentenoate (13.15 g, 41.2 mmol) in 20 mL THF is added dropwise, and the resulting solution is allowed to come to 25 °C over 60 min. The solution is cooled again to 0 °C and quenched with 6 ml of 1 :1 THF - ethanol, added cautiously, then 40 mL of pH 7.0 phosphate buffer. 40 mL 30% hydrogen peroxide is added and the reaction mixture is stirred at 25 °C for 14 h. The mixture is partially concentrated, added to saturated aqueous sodium chloride, and extracted with ether. The combined organic layers are washed twice with ice-cold saturated aqueous sodium sulfite, water, and saturated aqueous sodium chloride, and dried over magnesium sulfate. Concentration in vacuo and purification by silica gel chromatography (elution with hexanes - EtOAc, 3:2) provides tert-butyl (2S,3R)-2-benzyloxycarbonylamino-3-methyl-5- hydroxypentanoate as an oil (12.3 g, 89%). ESI-MS m/z 360 (M+Na)⁺ 338 (M+H⁾⁺

Η NMR (CDC1₃, 400 MHz) δ 7.34 (m, 5H), 5.40 (bd, IH), 5.09 (s, 2H), 4.11 (m, IH), 3.78 (m, IH), 3.65 (m, IH), 2.22 (m, IH), 1-7-1.6 (bs, IH), 1.63 (m, 2H), 1.45 (s, 9H), 0.84 (d, 3H) ppm.

Example 3m; tert-Butyl (2S,3R)-2-Benzyloxycarbonylamino-3-methyl-5-azidopentanoate

tert-Butyl (2S,3R)-2-benzyloxycarbonylamino-3-methyl-5-hydroxypentanoate (12.3 g, 36.4 mmol) is dissolved in 60 mL dichloromethane and 8.8 mL pyridine and cooled to 0 °C. Methanesulfonyl chloride (4.59 g, 40.1 mmol, 3.10 mL) is added via syringe and the resulting solution allowed to stir for 14 h. The reaction mixture is washed with 1 N HCl, saturated aqueous sodium chloride, and is dried over magnesium sulfate. Filtration and concenfration provides the crude methanesulfonate which is taken up in 50 mL of DMF and heated at 50 °C with LiN₃ (5.36 g, 109 mmol) for 3 h. The reaction mixture is added to water and exfracted three times with ether. The combined exfracts are dried over magnesium sulfate and concentrated to give the crude azide (10.3 g) which is purified by chromatography on silica gel (hexanes - EtOAc 8: 1) to give tert-butyl (2S,3R)-2-benzyloxycarbonylamino-3- methyl-5-azidopentanoate as an oil (9.40 g, 71%). Η NMR (CDC _. 400 MHz) δ 7.34 (m, 5H), 5.28 (bd, IH), 5.09 (s, 2H), 4.31 (m, IH), 3.39 (m, 2H), 2.18 (m, IH), 1.72 (m, IH), 1.45 (s, 9H), 1.44 (m, IH), 1.84 (d, 3H) ppm. ESI-MS m/z 385 (M+Na)⁺, 329 (M+Na-C₄H₈)⁺

Example 3n; tert-Butyl (2S,3R)-2-Benzyloxycarbonylamιno-3-methyl-5-(ιmmo- amιno)methylammomumpentanoate Nitrate

tert-Butyl (2S,3R)-2-benzyloxycarbonylammo-3-methyl-5-azιdopentanoate (1.02 g, 2.81 mmol) and TEA (0.39 mL, 2.8 mmol) are dissolved m 10 mL methanol and hydrogenated at 30 psi over 0.05 g of Lmdlar catalyst. After 4 h, the catalyst is filtered and the filtrate concentrated to give the primary amine as a clear oil (940 mg, 100%). The amme (906 mg, 2.69 mmol) is immediately taken up in 5 mL of DMF and a solution of 3,5- dιmefhylpyrazole-1-carboxamιdιne nitrate (542 mg, 2.69 mmol) and TEA (0.4 mL) in 5 mL DMF is added followed by an additional 0.4 mL of TEA. After 3 d at 25 °C, volatiles are removed under vacuum and the resulting residue triturated with EtOAc (40 mL) and sonicated to a fine suspension. The solid is collected and washed with EtOAc to provide 856 mg (72%) of tert-butyl (2S,3R)-2-benzyloxycarbonylamιno-3-methyl-5-(ιmmo- ammo)methylammonιumpentanoate nitrate as a glassy solid. ESI-MS m/z 379(M+H)⁺, 323 (M+H-C₄H₈)⁺ ^]H NMR (DMSO-d₆, 400 MHz) δ 7.53 (bd, IH), 7.45 (bs, IH), 7.33 (m, 5H), 7.4-6.5 (bs, 2H), 5.02 (m, 2H), 4.00 (m, IH), 3.05 (m, 4H), 1.98 (m, IH), 1.6-1.1 (m, 2H), 1.37 (s, 9H), 0.82 (bs, 3H) ppm.

Example 3o; tert-Butyl (2S,3R)-2-amιno-3-methyl-5-(ιmmo ammo)methylammomumpentanoate Nitrate tert-Butyl (2S, 3R)-2-benzyloxycarbonylamino-3-methyl-5-(imino- amino)methylammoniumpentanoate nitrate (856 mg, 1.94 mmol) is dissolved in 10 mL methanol and 2 mL of 1 ,4-cyclohexadiene. 10% Palladium on carbon (80 mg) is added and the mixture is refluxed for 60 min. The warm solution is filtered and the filtrate is concentrated in vacuo to give tert-butyl (2S,3R)-2-amino-3-methyl-5-(imino- ammo)mefhylammoniumpentanoate nitrate as a glass (599 mg, 100%). ESI-MS m/z 245 (M+H⁾⁺

Example 3p; (2S,3R)-2-tert-Butoxycarbonylamino-3-methyl-5-(nitroimino- amino)methylaminopentanoic Acid

tert-Butyl (2S,3R)-2-amino-3-methyl-5-(imino-amino)methylammoniumpentanoate nitrate (599 mg) is taken up in 95% TFA. After 6 h, the TFA is stripped and the resulting residue repeatedly stripped from ethanol, EtOAc, isopropanol then finally toluene to provide (2S,3R)-2-amino-3-methyl-5-(imino-amino)methylammoniumpentanoic acid nitrate frifluoroacetate as an oil (1.04 g). ESI-MS m/z 189 (M+H)⁺ 172 (M+H-NH₃)⁺.

(2S, 3R)-2-amino-3-methyl-5-(imino-amino)methylammoniumpentanoic acid nitrate frifluoroacetate (1.04 g) is dissolved in 1 mL concentrated H₂S0₄ and cooled in an ice/acetone bath with stirring. A precooled (-15 °C) mixture of fuming sulfuric acid (2.5 mL) and fuming nitric acid (1.7 mL) is added and the thick mixture is stirred for 2 h at -10 to -15 °C. Ice is added followed by the cautious addition of concentrated NH₄OH to pH 8. The mixture is then acidified to pH 5 with acetic acid. Volatiles are removed in vacuo to provides a yellow solid which is triturated for 1 h in methanol then sonicated for 10 min. Filtration through glass provides the product as a yellow solid contaminated with NH₄C1 (ESI-MS m/z 234 (M+H)⁺). The crude (2S,3R)-2-amino-3-methyl-5-(nitroimino-amino)methylaminopentanoic acid is dissolved in 15 mL of 5% sodium bicarbonate, concentrated to dryness, then taken up again in 10 mL of 5% sodium bicarbonate. THF (10 mL) is added, followed by di-tert-butyl dicarbonate (465 mg, 2.13 mmol). After stirring for 18 h, additional sodium bicarbonate (5 g) and di-tert-butyl dicarbonate (50 mg) is added. After 4 d the reaction mixture is extracted with ether, acidified to pH 1 with 6 N HCl, then extracted with dichloromethane, saturated with solid sodium chloride, then extracted further with dichloromethane. The combined dichloromethane layers are washed with saturated aqueous sodium chloride, dried over magnesium sulfate, and concentrated in vacuo to provide crude (2S,3R)-2-tert- butoxycarbonylamιno-3-methyl-5-(nιtroιmmo-ammo)methylammopentanoιc acid (125 mg). ESI-MS m/z 356 (M+Na)⁺ 334 (M+H)⁺ 278 (M+H-C₄H₈)⁺ Η NMR (CDClj, 400 MHz) δ 11.0-10.5 (bs, 2H), 8.68 (bs, IH), 87.9-7.5 (bs, IH), 5.39 (d, IH), 4.45 (d, IH), 3.69 (m, IH), 3.29 (m, IH), 2.18 (m, IH), 1.62 (m, IH), 1.48 (m, IH), 1.44 (s, 9H), 0.86 (d, 3H) ppm.

Example 3q; (2S,3R)-2-tert-Butoxycarbonylamιno-3-methyl-5-(mtroιmιno- amιno)methylammopentanoιc Acid l,3-Thιazol-2-ylamιde

(2S,3R)-2-tert-Butoxycarbonylammo-3-methyl-5-(nιtroιmιno- amιno)methylamιnopentanoιc acid (123 mg, 0.396 mmol) is dissolved in 1 mL of DMF and cooled to -23 °C. TEA (51 μL, 0.37 mmol) is added followed by isobutyl chloroformate (48 μL, 0.37 mmol). After 40 mm, 2-ammothιazole is added and the reaction mixture is allowed to come to 25 °C over 18 h. The reaction mixture is added to half-saturated aqueous sodium chloride and exfracted with EtOAc. The combined organic layers are washed with IN HCl, 5% sodium bicarbonate, saturated aqueous sodium chloride, and dried over magnesium sulfate. Concentration in vacuo and purification by chromatography on silica gel (elution with hexanes - EtOAc 1 :5 then EtOAc) provides (2S,3R)-2-tert-butoxycarbonylamιno-3- methyl-5-(nιtroιmmo-ammo)methylammopentanoιc acid l,3-thιazol-2-ylamιde as a foam

(101 mg, 66%). ESI-MS m/z 416 (M+H)⁺ 360 (M+H-C₄H₈)⁺

^]H NMR (CD₃OD, 400 MHz) δ 7.35 (d, IH), 7.03 (d, IH), 6.85 (bd, IH), 4.31 (m, IH), 3.27

(m, 2H), 2.04 (m, IH), 1.62 (m, IH), 1.44-1.27 (m, 2H), 1.36 (s, 9H), 0.86 (d, 3H) ppm.

Example 3r; (2S,3R)-2-Amino-3-methyl-5-(nifroimino-amino)methylaminopentanoic Acid 1 ,3-Thiazol-2-ylamide Hydrochloride

(2S,3R)-2-tert-Butoxycarbonylamino-3-methyl-5-(nifroimino- amino)methylaminopentanoic acid l,3-thiazol-2-ylamide (101 mg, 0.243 mmol) is dissolved in 1 mL THF and 1.5 mL of 4 N HCl in dioxane is added. After 2 h, THF is added and the white precipitate is collected by filtration. The resulting oily solid is treated with methanol and concentrated in vacuo. THF is added and the mixture is concentrated in vacuo; this THF addition and concenfration is repeated several times to give (2S,3R)-2-amino-3-methyl-5- (nitroimino-amino)methylaminopentanoic acid l,3-thiazol-2-ylamide hydrochloride as a solid (83 mmol, 97%).

ESI-MS m/z 338 (M+Na)⁺ 316 (M+H)⁺

Example 3; (2R,3S)-3-(Formyl-hydroxyamino)-2-(2-methyl-l-propyl)butanoic Acid [(1S.2R)- 2-Methyl-4-(nitroimino-amino)methylamino- 1 -(1 ,3-thiazol-2-ylcarbamoyl)- 1 -butyl]amide

To a 0°C solution of (2R,3S)-3-(formyl-2-tetrahydropyranyloxyamino)-2-(2-methyl- l-propyl)butanoic acid (34 mg, 0.12 mmol) in 1 mL anhydrous DMF is added diethyl cyanophosphonate (19 mg, 0.119 mmol) followed by NMM (12 mg). Stirring is continued for 30 min at 0 °C. (2S,3R)-2-Amino-3-methyl-5-(nitroimino-amino)methylaminopentanoic acid l,3-thiazol-2-ylamide hydrochloride (42 mg, 0.119 mmol) is added followed by additional NMM (36 mg). The mixture is heated at 40 °C for 16 h then allowed to cool to 25

°C. The reaction mixture is added to half-saturated aqueous sodium chloride and exfracted with 1:1 EtOAc - ether. The combined organic layers are washed with pH 4.3 phosphate buffer, 5% aqueous sodium bicarbonate, saturated aqueous sodium chloride, and dried over magnesium sulfate. Concentration and chromatography on silica gel (elution with 5% methanol in dichloromethane) provides 35 mg of (2R,3S)-3-(formyl- tetrahydropyranyloxyamino)-2-(2-methyl- 1 -propyl)butanoic acid [( 1 S, 2R)-2-methyl-4- (nitroimino-amino)methylamino-l-(l,3-thiazol-2-ylcarbamoyl)-l-butyl]amide as a foam. ESI-MS m/z 607 (M+Na)⁺

(2R,3S)-3-(Formyl-tefrahydropyranyloxyamino)-2-(2-methyl- 1 -propyl)butanoic acid [( 1 S, 2R)-2-methyl-4-(nitroimino-amino)methylamino- 1 -( 1 ,3-thiazol-2-ylcarbamoyl)- 1 - butyl]amide (30 mg, 0.049 mmol) is dissolved in 2 mL of 80% acetic acid and heated at 40 °C for 20 h. Concentration in vacuo, trituration with dichloromethane/ether, and collection of the product provides 26 mg of (2R,3S)-3-(formyl-hydroxyamino)-2-(2-methyl-l-propyl)butanoic acid [( 1 S, 2R)-2-methyl-4-(nifroimino-amino)methylamino- 1 -( 1 ,3-fhiazol-2-ylcarbamoyl)- 1 - butyl] amide as a solid. ESI-MS m/z 501 (M+H)⁺

Anal. Calcd. For C,₉H₃₂N₈0₆S 0.75 H₂0: C, 44.39; H, 6.57; N, 21.80; Found: C, 44.46; H, 6.39; N, 21.48.

PHARMACOLOGY

The efficacy of compounds of the present invention as inhibitors of matrix metalloproteases, TNFα converting enzyme and TNFα cellular release can be evaluated and measured using pharmacological methods known in the art or as described in detail below based on similarly established methodologies.

Pharmacological Example 1 A. Matrix Metalloprotease Inhibition Protocol

The potency of compounds of the invention as inhibitors of 19 kD truncated collagenase- 1 (MMP-1), 20 kD truncated collagenase-3 (MMP-13), stromelysm-1 (MMP-3), and 50 kD truncated gelatmase B (MMP-9) is determined according to the general procedure of Bickett et. al. (Anal. Biochem. 1993, 212, 58-64) using the fluorogenic substrate, DNP-Pro- Cha-Gly-Cys(Me)-Hιs-Ala-Lys(NMA)-NH₂ (DNP = 2,4-dιnιfrophenyl, NMA = N-

methylanthranihc acid). Assays are conducted in a total volume of 0.180 mL assay buffer (200 mM NaCl, 50 mM Tπs, 5 mM CaCl₂, 10 μM ZnS0₄, 0.005% Bπj 35, pH 7.6) in each

well of a black 96 - well microtiter plate 19 kD collagenase- 1, 20 kD collagenase-3, stromelysm-1, and 50 kD gelatmase B concentrations are adjusted to 500 pM, 30 pM, 5 nM, and 100 pM, respectively. A dose response is generated using an eleven - point, 3 - fold serial dilution with initial starting test compound concentrations of 100, 10, or 1 μM. Inhibitor and enzyme reactions are incubated for 30 minutes at ambient temperature and then initiated with 10 μM fluorogenic substrate (above). The product formation is measured at

Excιtatιon343/Emιssιon45o nm after 45-180 minutes using a Fluostar SLT fluorescence

analyzer. Percent inhibition is calculated at each inhibitor concenfration and the data are plotted using standard curve fitting programs. IC₅₀ values are determined from these curves. Assays are run at low substrate concentration ([S]«K_m) such that the calculated IC₅₀ values are equivalent to K, within experimental error.

B. TNFα Converting Enzyme Inhibition Protocol

The potency of compounds of the invention as inhibitors of cell - free tumor necrosis factor α converting enzyme is determined as follows; Membrane preparation from MonoMac 6 cells (subfractionated extract from equivalent of 6x10⁶ cells per 60 μl assay) is incubated for 1 hr with 200 nM radiolabeled substrate (Bιotιn-SPLAQAVRSSSRT-(³H)P-S-NH₂ , 4.1 Ci/mmol, ref # 0935 from Zeneca) in 10 mM hepes buffer, 250 mM sucrose, pH 7.5. The reaction is quenched by addition of streptavidm SPA beads (Amersham RPNQ0006), with excess binding capacity relative to substrate, suspended 250 mM EDTA, pH 8.0. Binding is complete within 15 minutes and plates are counted in a Wallac 1450 Microbeta liquid scintillation counter. Percent inhibition is calculated at each inhibitor concentration and the data are plotted using standard curve fitting programs. IC₅₀ values are determined from these curves. Assays are run at low substrate concentration ([S]«K_m) such that the calculated IC₅₀ values are equivalent to K, within experimental error.

C. Cell - Based TNFα Release Inhibition Protocol

The potency of compounds of the invention as inhibitors of release of soluble tumor necrosis factor α from stimulated monocytes in vitro is determined as follows; LPS/PMA solution for assay consisting of a) 4 μL of 5 mg/mL LPS stock and b) 6 μL of 10 mg/mL

PMA stock are added to 500 μL of medium (RPMI + 10% FBS + penicillin/streptomycin + 1- glutamme). This solution is then diluted 1 :1000 (40 ng/mL and 120 ng/mL) for use later in the assay. Compounds (10 mM) are serially diluted 1:3 m DMSO. Compound dilutions (20 μL) are added to a sterile round bottom 96 well plate (20 μL:200 μL total volume = 1 :10 for final concentrations of 50 μM for test compounds). MonoMac 6 cell suspension (130 μL, 1.5 xlO⁶ cells/mL) is then added to each well resulting in 2 x 10⁵ cells/well. LPS/PMA (50 μL) solution is then added to each well (final concentrations of 10 ng/mL and 30 ng/mL respectively). The plate is incubated at 37 °C for 2 h then spun at 1,500 rpm for 3 mm to pellet cells. The supernatant (120 μL/well) is removed to a new round bottom 96 well plate and diluted 1 : 10 in PBS. Then, 20 μL of the supernatant is transferred to a Cisfron TNFα

ELISA plate and processed according to the manufacturer's instructions to quantitate levels of

TNFα. Percent inhibition of TNFα release is calculated at each inhibitor concentration and the data are plotted using standard curve fitting programs. IC₅₀ values are determined from these curves.

Results are listed in Table 3.

Table 3

Pharmacological Example 2

Murme LPS - Stimulated Serum TNF Inhibition Protocol

The potency of compounds of the invention as inhibitors of serum TNFα elevation in mice treated with lipopolysacchaπde (LPS) is determined as follows; a) for subcutaneous (s.c.) administration, test compound is dissolved in DMSO and added to a mixture of 0.9% sodium chloride solution and 30% Trappsol HPB-20 (Cyclodexfrm Technology Development Inc., Gainesville, Florida USA) for a final DMSO concentration of 1%. The dosing solution is sonicated briefly and 0.2 mL is injected subcutaneously 10 min prior to LPS injection, b) for per oral (p.o.) administration, test compounds are formulated in 0.2 mL of PBS and 0.1% Tween 80 and given orally via gavage 10 min prior to LPS adminisfration.

C3/hen female mice are injected infraperitoneally with 200 μg/kg LPS (Escherichia coli, Serotype 0111:B4, Sigma Chemical Co, St. Louis, MO) in PBS and sacrificed 90 min later by C0₂ asphyxiation. Blood is immediately taken from the caudal vena cava and plasma prepared and frozen at -80 °C. Plasma concentrations of TNF are measured by ELISA (Genzyme Co., Cambridge MA).

Results are listed in Table 4.

Table 4

Throughout this application, various publications are referenced. These publications are hereby incorporated by reference in their entirety.

While the invention has been described and illustrated with reference to certain preferred embodiments thereof, those skilled in the art will appreciate that various changes, modifications and substitutions can be made therein without departing from the spirit and scope of the invention. For example, effective dosages other than the preferred dosages as set forth herein above may be applicable as a consequence of variations in the responsiveness of the mammal being treated for inflammatory conditions, or for other indications for the compounds of the invention indicated above. Likewise, the specific pharmacological responses observed may vary according to and depending upon the particular active compound selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be limited only by the scope of the claims which follow and that such claims be interpreted as broadly as is reasonable.

Claims

WHAT IS CLAIMED IS:

1. A compound of the formula

(ll) where

R, is

K where

alkylene, alkenylene, alkynylene, or a direct bond;

A₂ is

O, S, SO, S0₂, or a direct bond;

R₂ is

D₄\

D₃

^ -~"** ; where

D₄ is alkyl, aryl, heteroaryl, or hydrogen;

R₃ is hydrogen or lower alkyl;

R, is

— "v W

^ 2

K

where

E] is alkylene, alkenylene, alkynylene, or a direct bond,

E₂ is S, O, SO, S0₂, C(0)0, OC(O), NR₇, C(0)NR₇, NR₇C(0), S0₂NR₇, or a direct bond, where R₇ is as defined below; E₃ is alkylene, cycloalkylene, cycloalkenylene, arylene, heterocyclylene, heteroarylene, or a direct bond;

E₄ is

E₅ is lower alkyl or hydrogen;

R₅ ιs hydrogen or lower alkyl;

Re is z I ₂

X

where

heteroarylene or a direct bond;

Z₂ is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, aryl, NR₈R₉, OR₈, or hydrogen, where R₈ and R₉ are as defined below; and

R₇, R₈, and R₉ are, independently, hydrogen, alkyl, alkynyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or heteroaryl;

2. A compound of the formula:

(II) where R, is methyl, trifluoromethyl, ethyl, phenylsulfanylmethyl, phenylsulfonylmethyl, thiophene-2- sulfanylmethyl, thiophene-2-sulfonylmethyl, isopropyl, 3-methyl-l -butyl, benzyloxymethyl,

2-benzyloxy-l -ethyl, benzyl, n-propyl, 3,3,3-trifluoro-l-propyl, or cyclopropyl;

R₂ is isobutyl, cyclohexylmethyl, 3 -(2-furyl)-l -propyl, 3-(4-biphenyl)-l -propyl, 4- methylcyclohexylmethyl, cycloheptylmethyl, cyclohexyl, 5-methylthiophene-2-methyl, 4- phenyl-1 -butyl, 3-phenyl-l -propyl, or benzyl;

R₃ is hydrogen, methyl, or ethyl; 3 -(nitroimino-amino)methylamino- 1 -propyl, 3-(nitroimino-amino)methyl-ethylamino- 1 - propyl, 3-(nitroimino-amino)methyl-methylamino- 1 -propyl, 3-(nitroimino-amino)methyl- isopropylamino- 1 -propyl, 2-(nitroimino-amino)methylamino- 1 -ethylaminocarbonylethyl, 2- (nitroimino-amino)methylamino- 1 -ethylaminocarbonylmethyl, 4-(nitroimino- amino)methylamino-l -butyl, or 4-(nitroimino-amino)methylamino-2-butyl;

R₅ is hydrogen, methyl, ethyl, or n-propyl; and

Re is hydrogen, methyl, 5-ethyl-2-thiazolyl, cyclopropyl, cyclobutyl, cycloheptyl, 2,2,2- trifluoroethyl, cyclopentyl, 3-cyclopenten-l-yl, 2-pyridyl, l,3,4-thiadiazol-2-yl, or 2-thiazolyl.

A compound of the formula:

(ll) where R, is methyl, isopropyl, benzyl, n-propyl, 3,3,3-trifluoro-l-propyl, or cyclopropyl;

R₂ is isobutyl, cyclohexylmethyl, 4-methylcyclohexylmethyl , 5-methylthiophene-2-methyl, 3- phenyl-1 -propyl, or benzyl;

R₃ is hydrogen;

R₄ is

3-(nitroimino-amino)methylamino- 1 -propyl, or 4-(nifroimino-amino)methylamino-2-butyl;

R₅ is hydrogen; and

Re is hydrogen, methyl, or 2-thiazolyl.

4. A compound of the formula:

(II) where R, is methyl, n-propyl, or 3,3,3-trifluoro-l-propyl;

R₂ is isobutyl, 3-phenyl-l -propyl, or benzyl;

R₃ is hydrogen;

R₄ is

3 -(nitroimino-amino)methylamino- 1 -propyl;

R₅ is hydrogen; and

Re is hydrogen, methyl, or 2-thiazolyl.

5. A compound of claim 1, wherein the compound is selected from the compounds listed in Table 1.

6. A compound of claim 1, wherein the compound is selected from the compounds listed in Table 2.

7. A compound of formula (II) as claimed in any one of claims 1 to 6 for use in therapy.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 6.

. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in any one of claims 1 to 6 sufficient to inhibit the cellular release of mature tumor necrosis factor alpha.

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in any one of claims 1 to 6 sufficient to inhibit a matrix metalloprotease.

11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in any one of claims 1 to 6 sufficient to inhibit the shedding of cell surface protein ectodomains.

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in any one of claims 1 to 6 sufficient to inhibit CD23 proteolysis.

13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in any one of claims 1 to 6, sufficient to inhibit the growth of tumor metastases.

14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in any one of claims 1 to 6, sufficient to treat arthritis.

15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in any one of claims 1 to 6, sufficient to treat diabetes.

16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in any one of claims 1 to 6, sufficient to treat periodontal disease.

17. A method of inhibiting a matrix metalloprotease, comprising the step of administering to a mammal in need thereof a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 6.

18. A method of inhibiting the intracellular release of tumor necrosis factor alpha, comprising the step of administering to a mammal in need thereof a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 6.

19. A method of inhibition of shedding of cell surface protein ectodomains, comprising the step of administering to a mammal in need thereof a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 6.

20. A method of inhibition of CD23 proteolysis, comprising the step of administering to a mammal in need thereof a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 6.

21. A method of treating periodontal disease comprising of administering to a mammal in need thereof a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 6.

I l l

22. Use of a compound as claimed m any one of claims 1 to 6 m the preparation of a medicament for inhibiting the intracellular release of mature tumor necrosis factor alpha.

23. Use of a compound as claimed in any one of claims 1 to 6 in the preparation of a medicament for inhibiting a matrix metalloprotease.

24. Use of a compound as claimed in any one of claims 1 to 6 in the preparation of a medicament for inhibiting the shedding of cell surface protein ectodomains.

25 Use of a compound as claimed in any one of claims 1 to 6 in the preparation of a medicament for inhibiting CD23 proteolysis.

26. Use of a compound as claimed in any one of claims 1 to 6 in the preparation of a medicament for inhibiting the growth of tumor metastases.

27. Use of a compound as claimed in any one of claims 1 to 6 in the preparation of a medicament for treating arthritis.

28. Use of a compound as claimed m any one of claims 1 to 6 in the preparation of a medicament for treating diabetes.

29. Use of a compound as claimed in any one of claims 1 to 6 m the preparation of a medicament for treating periodontal disease.